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ABSTRACT
 
Thrall, Jessica Marie Hattle (Ph.D., Biochemistry)
Studies of the Mechanisms of TFIIH and Noncoding RNAs in Eukaryotic Transcription
Thesis directed by Professors James A. Goodrich and Jennifer F. Kugel
  
  The control of eukaryotic transcription is carefully orchestrated and involves many 
types of regulatory factors. Transcription is the underlying mechanism that controls all cellular 
processes and when left unchecked results in diseased cell states and cell death. Understanding 
the detailed mechanisms and processes of eukaryotic transcription is the goal of these studies.
 Inspired by our previous eukaryotic transcription kinetic studies, Chapter 2 describes 
identifying a factor that accelerates the rate of promoter escape. Spiking in vitro transcription 
assays with a nuclear extract resulted in an increase in the rate of in vitro transcription from 
the adenovirus major late promoter. With the understanding that many factors are involved in 
transcriptional regulation, we hypothesized that a factor could function to enhance the rate of 
transcription after being recruited to promoters. I set out to purify, identify, and characterize 
this factor. I developed a rate assay to monitor purification of the factor over several 
columns. The purified rate-accelerating factor was identified to be the general transcription 
factor TFIIH. Comparing my purified TFIIH to two standard TFIIH purifications revealed 
that high concentrations of TFIIH accelerated the rate of early transcription.
 Recent studies have identified thousands of long noncoding RNAs (lncRNAs) with the 
potential to regulate gene expression, some on a single gene level and others potentially 
iii
regulating multiple genes through mechanisms controlling chromatin structure. At the time this 
work was started, there were no genome-wide methods to determine whether these lncRNAs 
interact directly with chromatin, and if so, where. I developed a method named ChOP-seq to  
identify the genomic regions with which the lncRNA HOTAIR associates. I was ultimately able 
to show RNA-dependent enrichment of specific genomic regions using the ChOP technique, 
identifying a diverse set of genes that may be regulated by HOTAIR. We are positioned to apply 
our new knowledge of ChOP assays to other ncRNAs. This method has the potential to extend 
our understanding of the mechanisms that contribute to epigenetic programming. 
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CHAPTER 1
Eukaryotic Gene Expression and its Regulation
1
INTRODUCTION
 Eukaryotic transcription is a highly regulated, multi-step process in gene expression that 
involves RNA polymerase II (Pol II) catalyzing the synthesis of mRNA from a DNA template. 
Regulation of this step is crucial for maintaining cellular viability and differentiation and is 
controlled via many mechanisms at the chromatin, protein, and DNA sequence levels. 
Characterizing new mechanisms of transcriptional regulation is key to developing our 
understanding of gene expression. 
 The complex multistep process of transcription involves a broad range of factors specific 
to the DNA template and cell type. Transcription requires RNA polymerase II (Pol II) and, at 
most promoters, the general transcription factors (GTFs); TFIIA, TFIIB, TFIID, TFIIE, TFIIF, 
TFIIH, and the co-activator Mediator (1). For many genes, additional factors are also involved in 
the regulation of this process such as activators, repressors, co-activators, co-repressors, and 
chromatin remodeling factors (1-3). Furthermore, the promoter DNA from which transcription 
initiates contains elements that direct transcription (4). General transcription factors and other 
factors utilize these sequences to bind and regulate gene expression at specific promoters. The 
transcribed mRNA or noncoding RNA can also influence the process of transcription (5-8).
 Although Pol II is responsible for transcription of protein coding genes, the process is 
collaborative and dependent on many protein-protein interactions within and between general 
transcription factors. Each interaction can be regulated and networks of interactions achieve 
successful transcription. Furthermore, the level of transcription at promoters is controlled by 
gene and cell specific factors, like activators, repressors, co-activators, and even noncoding 
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RNAs. Here I will provide an overview of Pol II transcription and the DNA, RNA, and protein 
factors involved.
3
MAMMALIAN PROMOTER SEQUENCES AND STRUCTURE1
 A promoter is a defined region of DNA that directs the transcription of a gene. Eukaryotic 
promoters contain two main types of elements: 1) the core promoter elements, which recruit the 
general transcription machinery and Pol II and set the start site of transcription, and 2) regulatory 
elements, which recruit sequence specific factors such as activators and repressors that when 
bound control the level of transcription from the core promoter (1, 9). Each genomic promoter is 
unique with respect to the elements it contains, the mechanism of regulation, and the amount of 
transcription it directs. Eukaryotic promoters are discussed below, with an emphasis on well 
understood promoter elements in eukaryotic protein-encoding genes. The discussion below 
considers promoters of mammalian and Drosophila Pol II transcribed genes, which produce 
messenger RNA (Figure 1.1)1. Eukaryotic promoters contain elements with defined consensus 
sequences and critical spacing requirements.
Core Promoter Elements
 Core promoters in higher eukaryotes span from approximately 40 base pairs upstream to 
40 base pairs downstream of the transcription start site. The first discovered and most well 
studied of the core promoter elements is the AT-rich sequence known as the TATA box, which is 
located from approximately 24 to 31 base pairs upstream of the transcription start site. The 
consensus TATA box sequence is TATAWAAR (nontemplate strand; degenerate nucleotide 
symbols are described in the legend to Figure 1.1), which is conserved from archaebacteria to 
humans (10-12). During transcription, the TATA binding protein (TBP) of the transcription factor 
4
1 This section is adapted from Thrall, JMH and Goodrich, JA, 2012. Promoters. Encyclopedia of Genetics, 2nd 
edition. Brenner, S and Miller, J. (eds). Elsevier / Academic Press, 2012. (in Press)
5Figure 1.1. Eukaryotic Pol II promoter elements. Degenerate nucleotide symbols:  S= G or C; 
R= G or A; W= A or T; D= G, A, or T; K= G or T; Y= T or C; V= G, C, or A; N= any nt. The 
transcription start site is underlined in the Inr consensus sequences.
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IID (TFIID) multisubunit complex binds this sequence and bends the DNA to commence 
recruitment of the transcription machinery (13-15). TATA-containing promoters make up only 
10-15% of the mammalian promoters (12, 16). A second core promoter element, the Initiator 
element (Inr), has the consensus sequence YYANWYY (nontemplate strand) in humans (or 
TCAKTY in Drosophila) and encompasses the transcription start site (underlined in the 
consensus sequences) (9, 17). The TBP associated factors 1 and 2 (TAF1 and TAF2) of the TFIID 
complex bind the Inr element (18). The transcription factor IIB (TFIIB) response elements, the 
BREu and BREd, are positioned immediately upstream or downstream of the TATA box, 
respectively (19-21). The BREu has a consensus sequence of SSRCGCC and BREd has a 
consensus sequence of RTDKKKK (nontemplate strand). When present in a promoter, TFIIB 
binds these elements to aid in preinitiation complex formation. 
 There are also core promoter elements found downstream of the transcription start site. 
These elements include the Downstream Promoter Element (DPE), the Motif Ten Element 
(MTE), and the Downstream Core Element (DCE). The DPE has a consensus sequence of 
RGWYVT in Drosophila (nontemplate strand) and spans from 28 to 33 base pairs downstream 
of the transcription start site (22). It is bound by TAF6 and TAF9 to aid in recruiting the TFIID 
complex to the promoter. Mutation of the DPE in Drosophila promoters causes a reduction in 
transcription (23). The MTE was identified during biochemical and computational comparisons 
of Drosophila promoter sequences (24). The MTE is found just upstream of the DPE from +18 to 
+27 relative to the +1 start site and has a consensus sequence of CSARCSSAAC (nontemplate 
strand) (25). The MTE contributes to TFIID binding to the core promoter. Both the DPE and 
MTE have been found in Drosophila and human promoters. The DCE overlaps the same DNA 
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region as the DPE and MTE, however it is a distinct core promoter element (26). It consists of 
three short sequences: CTTC from +6 to +11, CTGT from +16 to +21, and AGC from +30 to +34 
(all nontemplate strand). The TAF1 subunit of TFIID can associate with the DCE.
 Eukaryotic core promoters are not universal in the elements that they contain (4). The 
MTE can act in synergy with either the TATA box or DPE (21, 25). However, the MTE, and 
frequently the DPE, can independently act with the Inr in TATA-less promoters (22, 25, 27). The 
modularity of eukaryotic core promoters allows for a high level of promoter variation, which is 
likely to impart specificity on the regulation of transcription of each gene (28). Many 
mammalian core promoters are less well-defined, with multiple transcription start sites that are 
dispersed over a range of 50 to 100 base pairs. These promoters often contain CpG islands, and 
generally lack TATA, DPE, and MTE motifs (9). The mechanism of recognition and transcription 
initiation at these promoters is currently an active area of research.
Regulatory Elements
 Eukaryotic regulatory elements can be separated into two groups: promoter proximal 
regulatory elements that are found within several hundred base pairs upstream of the core 
promoter, and distal regulatory elements that can be found up to tens of kilobase pairs upstream 
or downstream of the core promoter (reviewed in (3, 29)). The promoter proximal regulatory 
elements are typically bound by transcriptional activators and repressors, and the spacing 
between the regulatory elements and the core promoter can be important for the function of the 
elements. The distal regulatory elements typically contain multiple transcription factor binding 
sites and can act as enhancers that facilitate the activation of transcription, or as silencers that 
7
repress transcription from the core promoter. The regulatory proteins bound to enhancers or 
silencers communicate with regulatory factors bound at promoter proximal elements and the 
general transcription machinery bound at the core promoter, often over great lengths of 
intervening DNA. There is also evidence that enhancers are tuned to function with the specific 
arrangements of core promoter elements. For example, some enhancers can activate transcription 
from a TATA-containing core promoter better than a core promoter containing a DPE (30).
Chromatin Effects on Promoter Function
 In eukaryotes, DNA is packaged with histone proteins into chromatin, which in general 
restricts the accessibility of the transcription machinery to promoters (15). Loosely structured 
chromatin with sparse nucleosome occupancy promotes accessibility to a promoter region, 
whereas the opposite leads to transcriptional repression (31). Chromatin structure in promoters is 
regulated by specific chromatin modifiers that can remodel nucleosomes or post-translationally 
modify histones (32, 33). Some of these modifications can serve to recruit transcription factors to 
the promoter. In a broader view, it is not just the DNA that makes up eukaryotic promoters, but 
the chromatin. Regulation of chromatin structure is discussed later in this section.
Future Research on Promoters
 Transcription is a tightly controlled process that will be an important and active area for 
future research. Promoter elements will continue to be discovered and characterized, especially 
in eukaryotes. In this quest, experimental researchers will become more dependent on 
computational approaches to identify DNA sequences that could function as promoter elements. 
8
Together experimental and computational research will ultimately provide a more complete 
picture of promoters and their elements.
9
TRANSCRIPTION FACTORS AND THE TRANSCRIPTION REACTION
 The transcription reaction can be divided into at least 5 steps: pre-initiation complex 
formation, initiation, promoter escape, elongation, and termination (Figure 1.2) (34). Basal 
transcription begins with the recruitment of Pol II and transcription factors to form the 
transcription preinitiation complex (PIC). Initially the TATA-binding protein (TBP) subunit 
of TFIID recognizes and binds the 8-basepair TATA box for TATA-containing genes. TBP 
inserts phenylalanines into the minor groove and dramatically bends the promoter DNA 
rendering it accessible for subsequent GTF binding (35). TFIID is a 750 kDa multi-subunit 
complex consisting of TBP and 14 TBP-associated factors (TAFs), some of which also bind 
the core promoter DNA (21). The TAFs that recognize and bind to specific core promoter 
elements (e.g. TBP, TAF1, TAF2, TAF6, and TAF9) were discussed earlier in this chapter. 
TFIID is important for mediating interactions between many gene and cell-specific 
coactivators and activators and the general transcription machinery (3). However, in vitro 
TATA-containing promoters need only TBP and not the entire TFIID complex to achieve 
basal transcription (36, 37).
 Next, TFIIA and TFIIB recognize the promoter-bound TBP, or TFIID, and stabilize the 
DNA:protein complex (38). TFIIA binds upstream of the TATA box and aids in PIC 
formation by increasing the affinity of TBP for promoter DNA. TFIIB makes asymmetric 
contacts with the DNA both upstream and downstream of TBP to ensure directionality of 
transcription (19). TFIIB also serves to recruit Pol II and TFIIF to the promoter and aids 
Pol II in start site selection through it’s amino-terminal domain (39, 40). 
10
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Figure 1.2. Five distinct steps of eukaryotic basal transcription.
 Next, Pol II is recruited to the PIC along with TFIIF (41). TFIIF consists of the RAP30 
and RAP74 subunits and serves many functions throughout the transcription process 
including collaborating with TFIIB for start site determination, enabling promoter escape, 
and increasing Pol II efficiency during elongation (42, 43). Recently, TFIIF has been 
implicated in stabilizing TFIIB to the promoter (43). TFIIF also facilitates recruitment of 
TFIIE and TFIIH to the promoter. 
 Pol II is a 12 subunit complex that directs both messenger and noncoding RNA 
transcription. Pol II consists of four mobile lobes that, while carrying out transcription, make 
and break many protein-protein interactions with various GTFs and co-activators (44-46). 
The C-terminal domain (CTD) of the largest subunit of human Pol II contains 52 
heptapeptide repeats with the consensus sequence YSPTSPS and undergoes a 
phosphorylation cycle during the different stages of transcription where the 2nd and 5th/7th 
serines can be phosphorylated respectively by CDK9 of P-TEFb and CDK7 of TFIIH 
(47-49). The CTD serves as a flexible platform that interacts with various transcription 
factors and other proteins including components of the splicing machinery (see reviews 
(50, 51)).
 Transcription factors IIE and IIH primarily act after PIC formation. First, TFIIE enters 
the PIC and recruits TFIIH to facilitate promoter melting and initiation in the presence of an 
ATP energy source (52, 53). TFIIE is a heterotetramer composed of the subunits alpha (E56) 
and beta (E34) (54). TFIIE is thought to modulate the activity of TFIIH (55). The alpha 
subunit is responsible for interactions with Pol II, and TFIIH, and regulates the helicase and 
kinase activities of TFIIH (56, 57). Specifically, TFIIEα stimulates the ATPase and kinase 
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activities, but represses the helicase activity of TFIIH (58-60). The TFIIE beta subunit 
interfaces with Pol II, TFIIB, RAP30 of TFIIF, TFIIH, and dsDNA (61). TFIIE binds Pol II 
near the catalytic center and aids in preparing Pol II for initiation and facilitates promoter 
escape (62).
 Human TFIIH consists of 10 subunits. TFIIH comprises a core of XBP/ERCC3 (p89) 
helicase, XPD/ERCC2 (p80) helicase, p62, p52, p44, p34, and TFB5 (p8), which is bound by the 
cdk-activating kinase (CAK) subcomplex containing CDK7 (p40), cyclin H (p38), and the 
activating protein MAT1(p32) (60, 63, 64). XPD can also associate with the CAK subcomplex 
outside of TFIIH (65). TFIIH XBP helicase is responsible for promoter melting and open 
complex formation using the energy from ATP hydrolysis during transcription initiation (66, 67). 
XBP is also required for nucleotide transitions leading up to promoter escape and is implicated in 
promoter clearance (52, 53, 68). With the aid of Cyclin H, the CDK7 kinase subunit of TFIIH 
phosphorylates serine 5 and serine 7 within the repeats on the CTD of Pol II (48, 69). This CTD 
phosphorylation allows the transcription complex to progress from initiation into elongation. 
Upon association with TFIIH, CAK exhibits substrate specificity for phosphorylating TFIIEα, 
TFIIFα (RAP74), and TBP (56, 59, 65, 70). The CAK sub-complex can also phosphorylate other 
substrates to promote cell cycle progression (71). In addition to functioning in transcription, the 
subunits of TFIIH are involved in DNA repair and E3 ubiquitin ligase activity (72-75). TFIIH is 
a target for transcriptional activation in vitro to increase productive transcription, suppress 
promoter proximal pausing, and stimulate promoter escape (62, 76-81).
 In vitro transcription on a linear DNA template requires TFIIH, TFIIE, and hydrolyzable 
ATP to unwind the double-stranded DNA template and for Pol II to proceed through early 
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transcription (53, 82-84). Pol II can abortively initiate transcription on a linear template without 
TFIIE, TFIIH, and dATP (53). Without TFIIH, Pol II tends to stall in the promoter proximal 
region following promoter escape (78). However, TFIIE and TFIIH are not necessary for 
transcription using a promoter contained within a negatively supercoiled template, or on DNA 
with a preformed bubble (53, 82, 84-89). Furthermore, TFIIA is also not required for basal 
transcription in an in vitro transcription system constructed from purified factors (90).
 Following PIC formation, the TFIIH helicase melts the promoter DNA forming an open 
complex when ATP is present (82). Initiation begins with the formation of the first 
phosphodiester bond in the RNA followed by abortive transcription of 2 and 3 nucleotide (nt) 
RNAs (91-93). After transcription of a 4 nt RNA, the PIC, DNA, and RNA transform into a 
stable ternary complex; this transition is named escape commitment, and is facilitated by 
TFIIE and TFIIH (34, 94-96). The upstream edge of the transcription bubble lies at 
approximately the -9 position relative to the TSS and is expanded 18 nucleotides downstream 
during early transcription. When the RNA becomes 7 nucleotides long the upstream region of 
the bubble collapses to form a ~10 nt bubble (89). After this point an active TFIIH helicase is 
no longer required (89, 97-99). During promoter escape many protein-protein interactions are 
broken, facilitating the advancement of the complex into elongation. For example, a recent 
study found TFIIB releases from the promoter during promoter clearance immediately after 
formation of a 13 nt RNA, and the bubble collapse transition (100, 43). 
 After promoter escape, the transcription complex enters into elongation. TFIID, or TBP 
remains bound at the promoter, poised to commence another round of transcription, whereas 
Pol II, along with TFIIF, continues to elongate the nascent RNA (102). During early 
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elongation the other transcription factors (TFIIB, IIE, IIH) detach (43, 102-103). Once the 
Pol II clears the promoter, a new round of initiation can occur. Transcription termination 
releases the nascent RNA and Pol II, and re-initiation of transcription can occur on the 
promoter.
15
EUKARYOTIC EPIGENETIC AND CHROMATIN REGULATION
 Transcription is a much more complex process than discussed above, involving 
activators and cofactors for specificity, as well as transcription machinery components that 
are cell-type and promoter-specific. Furthermore, genomic DNA is condensed into chromatin 
which requires activators to recruit chromatin remodeling factors and modifiers to derepress 
the chromatin in order to grant the GTFs and Pol II access (31-33). DNA in the cell is 
wrapped around histone octamers to form nucleosomes consisting of 147 basepairs of DNA 
and two molecules each of histones H2A, H2B, H3, and H4. These can be further condensed 
into coiled coils to form highly condensed 30 nm chromatin fibers. Chromatin in regions of 
the genome exists as active euchromatin, repressed heterochromatin, or a combination of 
both (32). Promoter regions of constitutively active genes often have nucleosome-depleted 
regions (NDRs) immediately upstream of their transcription start sites (TSS) and contain 
poly(dAdT) stretches that block nucleosome formation (104-106). Furthermore, sites that 
bind activators frequently lie in the NDR regions.
 Chromatin structure is highly dynamic and controlled by chromatin remodeling 
complexes and histone modifying factors in response to gene expression requirements. 
Chromatin remodelers are enzymes that reorganize nucleosomes by sliding, displacing, or 
exchanging histones to mediate transcriptional accessibility (104). Nucleosome displacement 
occurs during transcription, along with nucleosome recycling and histone substitution during 
elongation (107, 108). ATP-dependent chromatin remodeling complexes are surmised to aid 
in Pol II progression through nucleosomes in gene bodies (107). Nucleosome positions vary 
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for different genes, and depending on the position of the nucleosome downstream of the start 
site it may promote promoter-proximal pausing for that gene (reviewed in (108, 109)).
 Histone modifying complexes covalently modify the histones in nucleosomes, most 
often on the highly conserved, unstructured N-terminal tails. These modifications may serve 
to disrupt intermolecular interactions to allow structural remodeling into either active or 
higher-ordered repressive chromatin, and to position distinctive chromatin marks for 
recognition by non-histone proteins (110) (reviewed in (32)). Histone modifications include 
methylation (me), acetylation (ac), ubiquitination (ub), phosphorylation (p), sumoylation 
(su), and ADP-ribosylation (ADPr) (31, 33, 108).
 Genome-wide studies have found patterns of chromatin marks surrounding 
transcription start sites with respect to active or repressed expression (reviewed in (31)). 
Specific acetylation, methylation, phosphorylation, and ubiquitination marks are associated 
with active gene expression, whereas, other methylation and ubiquitination marks, as well as 
sumoylation are associated with repression. These modifications and their associated 
transcriptional responses are summarized in Figure 1.3 (31) (data reviewed in (33, 108, 111)). 
The following marks display the hallmarks of transcription initiation on chromatin: Pol II 
occupancy, the presence of nucleosomes with trimethylated lysine 4 on histone H3 
(H3K4me3), and H3K9 and K14 acetylation (110, 112). Activators bound at promoters 
additionally recruit coactivators that may also remodel and modify chromatin. Low levels of 
methylation (mono- and di-methylation), acetylation, and phosphorylation often mark 
inactive genes and require further modification in order to be transcribed. Furthermore, 
modifications can work in conjunction with each other to tailor GTF-activator interactions 
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Figure 1.3. Distribution of histone modifications relative to an arbitrary gene promoter (left 
most) or gene body (light region). The column on the right indicates positive or negative 
correlation with gene expression. Curved modifications represent data from genome-wide 
studies and rectangle modifications from a few studies. (Figure from Li et al. 2007 (31)).
and expression levels. Chromatin marks also work on a broader scope by preserving 
inheritable epigenetic gene patterns that are vital to mammalian cellular differentiation and 
proliferation (33). A differentiated cell is imprinted with the genetic memory from the 
previous generation, however these mechanisms are not fully understood.
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LONG NON-CODING RNAS REGULATE THE TRANSCRIPTION REACTION
 Transcriptional regulators can target each of the individual transcription steps and factors 
to fine-tune gene expression. Activators can recruit factors to the promoter, stabilize the PIC, and 
interact with the GTFs, or stimulate promoter escape to increase expression (113). Furthermore, 
regulators can control gene expression on a global scale by regulating chromatin accessibility 
(31-33, 114). Long noncoding RNAs (lncRNAs) have been found to act as regulators of gene 
expression and some lncRNAs regulate multiple regions across the genome (114-116).
LncRNAs regulate gene expression
 LncRNAs are RNAs longer than 200 bases that do not encode a protein. Multiple 
genome-wide studies have identified thousands of uncharacterized lncRNAs associated with a 
variety of cell types (117-119). It has recently been speculated that there are over 8000 large 
intergenic ncRNAs (lincRNAs) and up to 40% of these are transcribed from regions containing 
H3K4me3/H3K36me3 marks, indicative of transcriptionally active chromatin domains (119). 
Many lncRNAs have also been found associated with the histone modifying complex PRC2, 
which is responsible for the repressive trimethylation of H3K27 (117, 118). These lncRNAs are 
believed to regulate the expression of a wide variety of genes due to the ubiquitous nature of 
PRC2. LncRNAs have been categorized to function as signals, decoys, guides, scaffolds, and as 
transcriptional effectors or enhancers through cis-acting or trans-acting mechanisms and, 
furthermore, some lncRNAs fit into more than one of these categories (115, 116, 120). LncRNA 
have been identified functioning at the epigenetic level, including controlling imprinting (H19 
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(121), Kcnq1ot1 (122)), development (HOTAIR (123), COLDAIR (124)), and also in cell cycle 
cycle (125), pluripotency, and differentiation (126).
 The most widely known lncRNA in epigenetic programming is the Xi specific transcript 
(Xist), which is responsible, along with co-regulator lncRNAs (Tsix, Xcite, and RepA), for 
the inherited X chromosome inactivation in female mammalian cells (127-129). Xist coats 
the chromosome from which it is expressed and recruits PRC2 to place repressive histone 
modifications for persistent transcriptional inactivation (130).
 Two intronic and paternally expressed lncRNAs, Kcnq1ot1 and Air, act in cis in a cell-
type and lineage specific manner to control gene expression. The 91 kb lncRNA Kcnq1ot1 
interacts with the histone methyltransferases G9a (for H3K9me3) and PRC2 (for H3K27me3) to 
place chromatin marks for bidirectional control to repress the Kcnq1 gene cluster (118, 122). Air 
is a 108 kb imprinted, paternally expressed intronic lncRNA that silences 8-10 genes over a 400 
kb region on the maternal allele, including the Igf2r gene cluster and the distal genes Slc22a3 
and Slc22a2. Air acts through recruiting G9a methyltransferase to these loci to convert chromatin 
to a silenced state (131, 132).
 Several lincRNAs have enhancer-like functions (133, 134). One group used knockdown 
studies to evaluate actively expressed lncRNAs greater than 1kb from known protein genes, and 
found seven novel lncRNAs that act as activators of neighboring genes in various cell types 
(133). A separate large scale study found transcription of evolutionarily conserved enhancer 
ncRNAs (eRNAs) found in enhancer regions correlated with transcription at nearby promoters. 
The function of eRNAs has not been established, however the authors hypothesized that eRNAs 
may deliver Pol II to promoters to activate transcription of nearby genes or that possibly 
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transcription of these eRNAs may serve in maintaining chromatin marks (134). The promoters of 
eRNAs are found marked with high levels of H3K4me1 and low H3K4me3 histone 
modifications (134, 135). 
 Other lncRNAs regulate transcription at the promoter, such as Evf-2 (136), Alu (137), 
and the DHFR lncRNA (138). Evf-2 is an intronic ncRNA from the ultraconserved region 
between the Dlx-5 and Dlx-6 genes. Evf-2 acts as a coactivator with the Dlx2 transcription 
factor to direct expression of the Dlx-5/6 genes (136). Alu RNA is induced upon heat shock 
and acts to repress transcription by disrupting contacts between Pol II, the GTFs, and the 
promoter DNA (137). 
 Some lncRNAs act as developmental switches to activate or inactivate families of genes 
during development (e.g. HOTAIR (123), COLDAIR (124), HOTTIP (139), and HOTAIRM1 
(140)). HOTAIR is a 2.2 kb lncRNA that is implicated in regulation of the HOXD genes during 
development. HOTAIR has been shown to act in trans as a scaffold and a guide to recruit the 
histone modifying complexes PRC2 and LSD1/REST/COREST, a H3K4 demethylase (141). 
HOTAIR is temporally and spatially expressed during development in specific posterior and 
distal cell types. A knockdown study in primary fibroblast cells implicates HOTAIR in repressing 
the gene expression of a set of HOXD genes. Homeobox transcription factor (HOX) genes are 
dispersed across four separate chromosomal loci and are expressed collinearly and temporally 
along their chromosome with respect to their spacial body positioning (142, 143). HOTAIR 
lncRNA has also been implicated in cancer progression and metastasis (144).
 Most of the lncRNA present in cells have yet to be investigated functionally. The 
scientific community is in need of a method to identify the locations of lncRNA association 
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with the genome. Genome-wide identification of the genomic regions directly associated 
with lncRNAs is a necessary next step to understanding their function as transcriptional 
regulators.
 Transcription is a complex process requiring many factors and an intricate regulatory 
system and there is still much to be learned about eukaryotic gene expression. The focus of 
the studies discussed in these following chapters are factors that regulate eukaryotic 
transcription at the promoter (Chapter 2) and at the epigenetic level (Chapter 3). Chapter 2 of 
this dissertation describes the purification and identification of a factor that accelerates the 
rate-limiting step of human RNA polymerase II transcription in an in vitro system. The work 
in Chapter 3 describes the development of a chromatin oligonucleotide precipitation assay, 
called ChOP-seq, as a tool to identify the genomic regions with which lncRNAs associate. 
Moreover, I used ChOP-seq to investigate the well studied lncRNA HOTAIR.
23
CHAPTER 2
Identification and characterization of a factor that accelerates the rate-limiting step of 
human RNA polymerase II transcription
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CHAPTER 2
SUMMARY
 Eukaryotic transcription consists of a series of complex events that are carried out and 
regulated by a group of factors that include the general transcription factors, cofactors, activators, 
repressors, and other accessory factors. Furthermore, each step in the process of transcription can 
be regulated. Promoter escape has been determined to be the rate-limiting step of transcription on 
the adenovirus major late promoter using a minimal transcription system consisting of TBP, 
TFIIB, TFIIF, and RNA polymerase II (Pol II). Using an in vitro transcription system, I set out to 
identify a factor from HeLa cells that accelerates the rate of promoter escape. To do this I used a 
combination of column chromatography, a rate assay to test column fractions, and mass 
spectroscopy. TFIIE was found to be necessary for the rate-enhancing activity, but not sufficient. 
After extensive purification, a group of factors were identified and TFIIH was determined to be 
the factor responsible for this rate accelerating activity. Moreover, the amount of TFIIH needed 
to accelerate the rate of promoter escape is different than that required to initiate transcription on 
a linear template.
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INTRODUCTION
 In vitro transcription experiments can be highly controlled, therefore, the mechanisms of 
transcription regulation can be studied in detail. For example, the reaction conditions can be 
individually modified to create order-of-addition experiments and experiments to monitor 
distinct reaction steps or recruitment of factors. Furthermore, in vitro experiments can be used to 
mechanistically study how transcription is regulated.
 The transcription reaction can be examined using a purified in vitro transcription system. 
We have used a minimal transcription system consisting of recombinant TBP, TFIIB, TFIIF, and 
purified native Pol II along with a negatively supercoiled DNA template. In this system the 
negatively supercoiled DNA negates the need for TFIIE and TFIIH (53, 85, 87). Furthermore, 
TBP can be used in place of holo-TFIID on a TATA containing promoter for examination of basal 
level transcription (36, 37, 85). Using this in vitro transcription system and the adenovirus major 
late promoter (AdMLP), our lab has kinetically determined that the Pol II transcription reaction 
minimally consists of the following steps: preinitiation complex formation, initiation, escape 
commitment, promoter escape, transcript elongation (Figure 2.1) (34). Activators and repressors 
can potentially regulate each of these steps (145-152). 
 Initially, Pol II and the general transcription factors must be recruited to assemble on the 
promoter DNA to form preinitiation complexes. In an ordered assembly at TATA-containing 
genes, TBP binds in the DNA minor groove and bends the DNA (14, 35). TFIIA and TFIIB can 
then bind their respective DNA response elements and enter the complex (38). TFIIF and Pol II 
then bind and recruit TFIIE and TFIIH (58). Once assembled, the TFIIH helicase melts the 
promoter DNA to form an open DNA complex and the PIC is then ready to engage in 
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Figure 2.1. Rate constants of eukaryotic transcription on negatively supercoiled AdMLP 
templates. Experimentally  determined rate constants using the AdMLP are listed above each 
step, where R= general transcription factors (TBP, TFIIB, TFIIF, and Pol II), P= promoter 
DNA (AdMLP), PIC= preinitiation complex, RPI= initiated complex containing a 3 nt RNA, 
RPEC= escape-committed complex containing a 4 nt RNA, RE= elongation complex 
containing a 8 nt RNA or 390 nucleotide RNA (34, 97).
 
kI> 0.1 s-1 kPCF(obs)> 0.1 s-1 kEC> 0.1 s-1 kPE> 0.002 s-1 kE> 0.03 s-1
(8nt RNA)(4nt RNA)(3nt RNA) (390nt RNA)
KI> 0.1 s-1KPCF(obs)> 0.1 s-1 KEC> .  -1 KPE= 0. 02 s-1 KE  .  s-1
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initiation (67). During initiation, the polymerase produces 2 to 3 nucleotide abortive transcripts 
(93). As the 4th nucleotide is added, stable ternary complexes form between the RNA, DNA, and 
proteins (95, 153). This is termed escape commitment (34). The transcripts then elongate to 8 
nucleotides where the complexes transition from initiation complexes into elongation complexes, 
completing promoter escape (97). During early transcription, multiple protein-protein and 
protein-nucleic acid interactions are broken and new ones are created as the polymerase moves 
away from the transcription start site (154). 
 Our kinetic studies determined promoter escape to be the rate-limiting step on the 
AdMLP in the minimal transcription system (34, 91). More specifically, we have determined that 
the rate-limiting step during promoter escape on the AdMLP promoter occurs after the synthesis 
of an 8 nt RNA and during the translocation of the Pol II active site to the 9th register (97). The 
rate of promoter escape varies on several tested promoters, however, it remains the rate-limiting 
step in vitro (155). Other events that occur during promoter escape include changes in the 
transcription bubble, release of TFIIB, transcript slippage, pausing of the ternary complex, and 
stable RNA:DNA hybrid formation (89, 98, 102, 156, 157). After promoter escape, the transcript 
is elongated and ultimately transcription is terminated.
 Being the rate-limiting step, promoter escape is a likely target for regulation (91). How 
the rate of this step can be enhanced was not understood and therefore was the goal of the studies 
described in this chapter. Using chromatography techniques and transcription rate assays, I 
purified a factor that accelerates the rate of promoter escape. The purified factor containing this 
rate-enhancing activity was identified to be the previously characterized and well-studied general 
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transcription factor, TFIIH. These findings illustrate a new activity for TFIIH in regulating the 
early steps of transcription.
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RESULTS
HeLa and Jurkat nuclear extracts contain an activity that accelerates the rate of promoter 
escape on an AdMLP template
 The transcription assays performed in these studies utilized the adenovirus major late 
core promoter (AdMLP) from -53 to +10, fused to a 380-base pair G-less cassette in a negatively  
supercoiled plasmid. This promoter contains A nucleotide bases at +1 and +16 (non-template 
strand), enabling us to make a 16 nt RNA in vitro by initiating transcription with a limited 
nucleotide mixture containing ApC, UTP, [α-32P]-CTP, and the chain terminator 3’-O-methyl 
ATP (Figure 2.2A). Figure 2.2B depicts the transcription assay timeline. Preinitiation complexes 
containing purified TBP, TFIIB, TFIIF, and Pol II were allowed to assemble on the promoter 
DNA for 10 minutes at 30oC then the nuclear extract or sample being tested for rate-enhancing 
activity was added and allowed to incubate for 5 minutes after which limited nucleotides were 
added. Transcription was quenched at multiple time points to obtain the rate of transcript 
formation. Transcript quantity was determined using gel electrophoresis and phosphorimagery, 
and plotted versus time to determine the single-exponential rate constant for the reaction. The 
rate constants were calculated using the equation y = ymax(1-e-kt), where y is the quantity of 
transcript. Negative controls for rate-enhancement used buffer instead of nuclear extract or 
chromatography fraction, and positive controls included the input to the column. 
 Addition of HeLa nuclear extract (HNE) to the transcription assay outlined in Figure 2.2B 
caused an 8-fold increase in the rate of transcription, taking it from 2.1 x 10-3 s-1 to 17.6 x 10-3 s-1 
as seen in Figure 2.3. Jurkat nuclear extract also increased the rate (data not shown). The rate-
limiting step of transcription on the AdMLP was previously found to be promoter escape, or the 
step between escape commitment and transcript elongation, therefore we proposed the rate 
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 Figure 2.2. A) A method for separating early steps of transcription from transcript 
elongation. The rate of promoter escape is determined using 32P-labeled CTP and the 
dinucleotide ApC to initiate transcription and the chain terminator 3‘O-Methyl ATP to 
produce a 16-nucleotide radiolabeled RNA easily resolved by gel electrophoresis and 
detected by  phosphorimagry. The AdMLP non-template strand sequence is shown above 
the transcript sequence. B) Experimental time course shows optimized order of addition 
and incubation times. NE= nuclear extract or fraction from chromatography.
RNA:
Time (min): -18 -15 - 5 0 t
TBP
TFIIB
TFIIF
Pol II
AdMLP +/- NE ApC
CTP
UTP
3‘OMeATP
Stop
Transcript (16 nt)
B.
A. non-template AdMLP DNA:     ACTCTCTTCCCCTCCA....G-less
ACUCUCUUCCCCUCCAme
16nt RNA product
ApC, UTP, *CTP, 
3’O-MeATP
+1 +5 +10 +15
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 Figure 2.3. HeLa nuclear extract accelerates the rate of promoter escape. Rate of full length 
transcript synthesis with (squares) and without (circles) HeLa nuclear extract. k+extract= 17.6 x 
10-3 s-1, k-extract= 2.1 x 10-3 s-1. Data were fit to the equation y= ymax(1-e-kt).
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increase was due to the effect of increasing the rate constant of promoter escape. Control 
reactions showed that the small amount of nuclear extract added to reactions did not produce 
transcription without the addition of purified transcription factors (data not shown). It was 
previously determined in our lab that the transcription factors TFIID, TFIIA, TFIIE, TFIIH, 
mediator, or the elongation factor TFIIS at levels used for typical in vitro transcription assays 
were not sufficient to produce the accelerated rate (data not shown).
A two-timepoint activity assay can be used to detect the rate enhancement.
 I can quantify the rate of transcription by performing a transcription assay in which the 
reaction is terminated at numerous time points and the radiolabeled transcript for each time point 
is measured. However, obtaining a comprehensive rate curve for fractions eluting from a 
chromatography column would be slow and tedious. In order to easily screen chromatography 
fractions, I developed the two-timepoint activity assay shown in Figure 2.4. Comparing the data 
from the full rate curve described above to that from our two-timepoint assay, I found that 
quantifying or visualizing the ratio of transcript produced at 15 and 600 seconds gave an easily 
discernible difference between rate-accelerated and basal level transcription. I used this two-
timepoint assay throughout purification of the activity. This assay also included TFIIE, TFIIH, 
and dATP in addition to the factors in the minimal system previously described. Including TFIIE, 
TFIIH, and dATP throughout the purification enabled transcription to occur even if factors in the 
extract nicked the supercoiled template. 
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Figure 2.4. Activity assay  used to identify  the factor(s) in HeLa nuclear extracts (HNE) 
responsible for accelerating the rate of promoter escape. The in vitro transcription assay uses 
the AdMLP promoter and radiolabeled CTP to monitor 16-nucleotide product formation at  15 
and 600 second timepoints. By calculating or visualizing the ratio of product at 15 s to 600 s I 
can identify the chromatography fractions that contain the activity.
Gel Electrophoresis and Phosphorimagry
Time (min): -18 -15 - 5 0 t = 15 or 600s
TBP
TFIIB
TFIIF
Pol II
TFIIE
TFIIH
AdMLP +/- NE ApC
CTP
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Purification of the activity from HeLa nuclear extracts
 After developing the two-timepoint screening assay that would be used to identify the 
chromatography fractions that contained the activity during purification, I began pilot studies 
using small batches of HeLa nuclear extract to test how the activity fractionated after step-wise 
salt elution over various chromatography columns. Fractions were assayed for total protein 
concentration using the Bradford assay and activity was detected using the two-timepoint assay. 
The samples were pooled according to activity. Titration of the eluates into the transcription 
assay determined the volume required to observe the accelerated rate of transcription. A variety 
of chromatography columns were tested and the final purification scheme that was used in two 
subsequent large scale purifications from 50 L of HeLa cells is shown in Figure 2.5. Total protein 
and activity units (U), defined by the volume used to elicit an accelerated rate of transcription, 
were used to determine percent recovery and fold purification (Table 2.1). The minimum volume 
required for rate-enhancement, and protein concentration, was not determined for the later 
purification steps due to dilution of activity, or in some instances to preserve material, however 
total activity, percent recovery, and fold purification for the latter chromatography steps were 
expected to be much greater.
DEAE chromatography
 I utilized DE52, di-ethyl-amino-ethyl (DEAE), gravity flow anion exchange resin with a 
step-wise salt elution to begin purifying the activity. The 50 mL column was equilibrated and the 
nuclear extract loaded with Buffer D containing 50 mM KCl (D.05) and then the column was 
washed with 5 column volumes of Buffer D.05, D.3 (0.3 M KCl), and D.5 (0.5 M KCl) for 
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Figure 2.5. Purification scheme of activity that accelerates the rate of promoter escape from 
HeLa nuclear extracts. Arrows indicate the approximate KCl concentrations (angled lines 
indicate gradient salt elution) where activity  eluted for each column. Eluate from the 
DEAE-5PW was prepared and submitted for mass spectrometry.
Mass Spectrometry
SDS-PAGE
0.5 M
Heparin
DEAE-5PW
0.1 M
1.0 M
0.1 M
HeLa Nuclear Extract
DE52
Phosphocellulose
Superose 6
Source 15S 1.0 M
0.1 M
550-600 kDa
0.1 M 0.3 M 0.5 M 1.0 M
Source 15Q 1.0 M
0.1 M
0.1 M 0.3 M 0.5 M 1.0 M
2 MDa 30 kDa
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Table 2.1. Purification table of rate-enhancing activity. Protein concentration was measured 
by Bradford Assay. Activity unit (U) was measured as the volume in µL used to elicit 
accelerated transcription. Note: the minimum volume required for rate-enhancement was not 
determined, therefore total activity, specific activity, and fold purification numbers are lower 
limits. nd= not determined.
Chromatography Protein Volume Concentration Activity Total Activity Spec. Act. % Fold 
 Column (mg) (ml) (mg/ml) (U) (U*mL) (U/mg) Recovery Purification
HeLa Nuclear Extract 238 56 4.2 1.0 56000 236 100 1
DEAE 52 9.1 90 0.10 1.0 90000 9934 161 42
Phosphocellulose nd 25 nd 1.0 25000 nd 45 nd
Source 15S Sepharose 1.9 4.5 0.42 1.0 4500 2400 8 10
Source 15Q Sepharose 1.3 1.4 0.99 0.5 2700 2022 5 9
Superose 6 nd 1.5 nd 2.0 750 nd 1.3 nd
Heparin nd 0.3 nd 1.0 260 nd 0.5 nd
DEAE-5PW nd 1.5 nd 2.0 750 nd 1.3 nd
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stepwise elution. Eluates were assayed for protein concentration using a Bradford protein assay 
and pooled accordingly for each salt step. The pooled fractions for each salt elution were tested 
in the two-timepoint rate assay. Figure 2.6A shows that the activity eluted in the 0.3 M KCl 
fraction, as seen by similar transcript levels in the 15 and 600 s timepoints. An S Sepharose 
(Spool) from an earlier test fractionation shows a low level of activity as a positive control. Some 
of the activity was lost in the flow through (DE52.ft), however this was barely detectable in the 
experiment shown. Lack of activity in the input was likely due to an insufficient quantity added 
to the reaction. The assay also confirms that the activity survives dialysis into buffer D.1, which 
was needed for the next purification step (sample D.3d in Figure 2.6A, where d= dialysis into 
Buffer D.1).
Purification of the activity using phosphocellulose chromatography
 I next ran the dialyzed 0.3 M KCl DE52 pool (D.3d) over a phosphocellulose (P11) resin 
which contains an orthophosphate functional group that acts to resolve proteins through 
phosphate affinity and weak cation exchange. Phosphocellulose (Pcell) columns are often used as 
initial columns for purifying transcription factors. The D.3d fraction was loaded onto a 20 mL 
phosphocellulose column followed by step elutions of 0.1 M KCl, 0.3 M KCl, 0.5 M KCl, and 
1.0 M KCl in Buffer D. Each pooled salt elution was tested and the activity was found to be in 
the 0.5 M KCl fraction (D.3P.5) (Figure 2.6A). This fraction was then dialyzed to 0.1 M KCl 
prior to running the next chromatography column.
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-C. Source 15Q: 40 4943 4738 55 6159ft 57+ 45 5351IN 64 67 70 73
-B. Source 15S 45 5748 54ft 63 6967IN* 65+ 51 6159IN 71 74 77 80
15
A. DE52.ft DE52.3IN D.3P.ft D.3P.3Spool
600
DE52.3dBuffer D.3P.5 D.3P.5dDE52 and Pcell:
15 600 15 600 15 600 15 600 15 600 15 600 15 600 15 600 15 600Time (s):
D.
Molecular Weight (kDa): 2000 669 443 150200 66 29
1 IN IN 4 7 10 12 15 17 19 21 23 25 27 30 32 34 38 40 43Superose 6:
Figure 2.6. Purification of activity  over first  five chromatography  columns. A) Fractions from 
DE52 and Phosphocellulose columns tested at 15 and 600 seconds. DE52.3d and D.3P.5d 
fractions were dialyzed to 0.1 M  KCl. B) Fractions from Source 15S column. Negative 
control samples substituted buffer for sample tested and positive control samples contained 
unpurified HNE. *IN= input + unpurified HNE. C) Fractions from Source 15Q column. D) 
Fractions from Superose 6 column. For B), C), and D) the activity was detected by  comparing 
levels of transcript  production after 15 seconds of transcription. Protein concentration was 
also determined (not shown). Numbers above gels correspond to chromatography fractions 
and the lines below the numbers indicate fractions that contain accelerated rate activity. IN= 
input to column. ft = column flow through.
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Purification of the activity using Source 15S chromatography
 I next tried purification of the D.3P.5 fraction using a 1.6 mL Source 15S resin and HPLC 
chromatography. S sepharose is a strong cation exchanger containing methyl sulfonate functional 
groups. I used a mobile phase of 10 column volumes of Buffer D with an increasing salt gradient 
from 0.1 M KCl to 0.7 M KCl. Preliminary S sepharose pilot studies using step-elution showed 
that the activity eluted in the 0.3 M salt step, therefore I tested a variety of fractions spanning 
from ~0.15 M to 0.3 M KCl (Figure 2.6B) looking at transcript production after 15 seconds with 
NTPs. Fraction 45 was determined to contain 0.1 M KCl and fraction 94 contained 0.3 M KCl. 
Fractions 53-75 were pooled. The corresponding chromatograph showed one large A280 peak 
spanning these fractions (data not shown). The flow through did not elicit any rate-enhancing 
activity. The S-pool was then diluted ~2.22-fold to 0.1 M KCl with Buffer D (0 M KCl) for 
fractionation over a Source 15Q column.
Purification of the activity using Source 15Q chromatography 
 I next used a Source 15Q anion exchange resin on our HPLC. This resin contains an 
immobilized quarternary amine functional group. I used a 10 column volume linear salt elution 
from 0.1 M to 0.7 M KCl, similar to the Source 15S column. Again, previous small scale 
purifications indicated that elution of the rate-enhancing activity would be between 0.2 and 
0.3 M KCl, and the fractions were tested in the transcription assay accordingly (Figure 2.6C). 
Fractions 45-64 showed robust activity and fractions 44-65 were pooled. The corresponding A280 
chromatograph contained 3 peaks, peak 1 at ~0.28 M, peak 2 at 0.4 M, and a third at 0.7 M KCl. 
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Activity correlated with peak 1, however peaks 1 and 2 overlapped and therefore did not resolve 
fully. Samples were stored at -80oC prior to the next fractionation.
Purification of the activity using Superose 6 size exclusion chromatography, and small scale 
batch test of phenyl sepharose and hydroxyapatite CHT
 Next I subjected the D.3P.5SQ activity to Superose 6 (S6) gel filtration chromatography 
using Buffer D.1 as the mobile phase. Superose 6 is a size exclusion column of highly cross-
linked agarose beads. The Q-pool was concentrated ~2.5 times for loading onto a 24 mL 
Superose 6 column. Figure 2.6D shows that the activity eluted in the fractions corresponding to a 
550-600 kDa protein, as determined by a set of standards fractionated on a separate, but identical 
chromatography run. Silver stain analysis of the activity indicated the fraction contained a 
mixture of multiple proteins (not shown). Based on the activity assay and similar silver stain 
patterns, fractions 16-18 were pooled for the next purification step.
 Next, small scale pilot purifications were tried with the P.5D.3 pool. I tested phenyl 
sepharose and hydroxyapatite CHT resins in batches using 50 µL or 100 µL of resin. The resins 
were nutated with P.5D.3 for 30 min at 4oC, prior to step elutions. Hydroxyapatite resin contains 
positively charged calcium and negatively charged phosphate binding sites and dually poses as a 
cation exchange and a calcium affinity column. Following the acidic protein purification protocol 
from BioRad, the proteins were eluted with increased phosphate buffer concentration (10 mM, 
250 mM, then 500 mM phosphate buffer, pH 7.6 ) and two stepwise salt elutions (0.25-0.5 M 
KCl). The hydroxyapatite CHT resin did not result in greater purification as almost all the 
fractions contained activity. Hydroxyapatite also posed a further complication as it required a 
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buffer change into phosphate buffer. However, silver stain of the flow-through and eluate did 
show the majority of proteins resided in the high phosphate fraction. Activity did not bind the 
phenyl sepharose resin (50 mM buffer, pH 7.6, 1.5 mM KCl, then 50 mM buffer with 0 M salt) 
and was found in the flow through. Data from these two batch purifications is not shown.
Purification of the activity using Heparin chromatography
 I next fractionated the D.3P.5SQ6 fraction over a 100 µL heparin affi-gel HPLC affinity 
column using our SMART system. I eluted with a linear salt gradient from 0.1 M to 0.5 M KCl. 
Figure 2.7A shows a preliminary heparin chromatography run using D.3P.5SQ, but prior to the 
Superose 6 column. The A280 chromatograph for this run showed a sharp peak corresponding to 
the flow through and a broad peak centered at fraction 26 and spanning fractions ~16 to ~35. 
There was some activity in the flow through, most likely due to surpassing the column’s 
capacity. For later runs, a larger column was packed and used. Fractions 20-31 were pooled. For 
large scale purification after the Superose 6 column, activity was seen in fractions pertaining to 
0.32 M - 0.49 M KCl. The heparin column also served to concentrate the activity 5-fold.
Purification of the activity using DEAE-5PW chromatography
 The D.3P.5SQ6Heparin pool was diluted 3-fold to 0.1 M KCl with Buffer D.0 (0 M KCl) 
and loaded onto a 100 µL DEAE-5PW weak anion exchange column. A 10 column volume salt 
gradient from D.1 to D1.0 was used. Fractions were subjected to the transcription rate assay and 
analyzed by SDS-PAGE and silver staining (Figure 2.7B and C). The A280 chromatograph 
showed two partially overlapping peaks. The activity was present throughout most of the 
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Figure 2.7. A) Transcription assay testing fractions from heparin column. Figure shows 
transcript production after 15 seconds of transcription. + is a positive control from another 
fractionation. B) Fractions from the DEAE-5PW column. C) Silver stain of DEAE-5PW 
fractions. DEAE-5PW fractions 10, 11, and 12 showed robust transcript production after 15 
seconds. M= molecular weight markers, and corresponding molecular weights are listed on 
the left of the gel.
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fractions, but was concentrated in the first peak (fractions 8-12). The saddle between the two 
peaks was fraction 13, and was about 5/6 the height of the first peak and about 1/3 height of the 
second peak. A longer column and salt gradient may have yielded a higher resolution 
purification. Fractions 10-12 were pooled for mass spectrometry analysis.
Mass spectrometry and protein identification 
 The DEAE-5PW pool (D.3P.5SQ6H-5PW) containing the activity was TCA precipitated 
and Figure 2.8 shows the sypro ruby stained SDS gel of the sample. Twenty-two gel sections 
were excised, in-gel trypsin digested, and eluted before submission to the University of Colorado 
Mass Spectrometry facility for analysis by LC-MS/MS with electrospray ionization and an ion 
trap. MASCOT analysis of the peptides is shown in Table 2.2. Among the proteins, 9 subunits of 
TFIIH were identified with abundant peptides and high MASCOT scores. Western blot analysis 
verified the presence of TFIIH in the final purified fractions (data not shown).
Activity on a negatively supercoiled versus linear template 
 Given that I identified TFIIH, I wanted to know whether the rate-enhancing activity was 
specific to the supercoiled template or if the activity could also evoke rate acceleration on linear 
DNA. Transcription from a linear template requires TFIIE, TFIIH, and ATP (or dATP) energy to 
form an open complex and advance through promoter escape, whereas a supercoiled template 
does not have this requirement. I tested the partially purified activity on a linear AdMLP 
template, quenching transcription at 15 and 600 seconds. Upon addition of the partially purified 
activity I saw accelerated rate activity (Figure 2.9). Therefore, the activity was not specific to a 
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Figure 2.8. Sypro ruby stain of mass spectrometry  gel. Numbers to the right indicate gel 
sections that were submitted as separate samples for mass spectrometry  identification. TFIIH 
peptides were identified in gel sections:  10, 11, 13, 15, 19, 20, and 22.
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Table 2.2. Mascot identification of peptides. LC/MS/MS was performed on gel slices of 
purified activity. Mascot search engine identified the above proteins using the IPI human 
database. MASCOT scores of at least  40 and proteins with 3 or more peptides matched were 
included in this table. TFIIH subunits are highlighted in bold. emPAI = exponentially 
modified protein abundance index.
Gel Mass Spectrometry Identification Alias Mass  emPAI MASCOT # Peptides
Section (kDa) Score  matched
2 Isoform 1 of DNA (cytosine-5)-methyltransferase 1 DNMT1 190 0.02 60 6
Isoform 1 of DNA-dependent protein kinase catalytic subunit PRKDC 469 0.01 51 15
3 Isoform 3 of DNA (cytosine-5)-methyltransferase 1 DNMT1 144 0.02 72 4
Isoform 1 of DNA (cytosine-5)-methyltransferase 1 DNMT1 189 0.05 68 6
4 TOP2A 183 kDa protein TOP2A 183 0.07 91 9
TOP2B Isoform Beta-2 of DNA topoisomerase 2-beta TOP2B 183 0.04 76 8
1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 3 PLCB3 139 0.02 49 5
5 SCC-112 protein SCC-112 151 0.02 43 7
6 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 119 0.06 71 7
7 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 119 0.5 336 26
8 Superkiller viralicidic activity 2-like SKIV2L2 118 0.09 63 11
9 Kinesin-like protein KIF2A 78 0.45 154 23
10 TFIIH basal transcription factor complex helicase XPB subunit ERCC3 89 0.2 143 14
11 Isoform 1 of WD repeat protein 48 WDR48 76 0.29 193 14
TFIIH basal transcription factor complex helicase subunit ERCC2 87 0.16 97 8
KIF2A Kinesin-like protein KIF2A 78 0.04 73 3
HSPA5 protein HSPA5 72 0.05 44 3
12 Lysyl-tRNA synthetase KARS 68 0.05 75 3
DNA-binding protein RFX5 65 0.1 55 5
13 TFIIH basal transcription factor complex p62 subunit GTF2H1 62 0.44 134 12
14 Eukaryotic translation initiation factor 2 subunit 3 EIF2S3 51 0.37 88 9
Histone-binding protein RBBP7 48 0.07 53 4
Histone-binding protein RBBP4 48 0.07 53 4
15 EIF2S2 protein EIF2S2 38 0.95 282 16
TFIIH basal transcription factor complex p52 subunit GTF2H4 52 0.2 88 9
16 Eukaryotic translation initiation factor 2 subunit 3 EIF2S3 51 1.4 464 65
Hypothetical protein n/a 51 0.77 221 31
17 Eukaryotic translation initiation factor 2 subunit 2 EIF2S2 38 3.43 477 54
Eukaryotic translation initiation factor 2 EIF2S3 51 0.13 92 3
18 Eukaryotic translation initiation factor 2 subunit 2 EIF2S2 38 0.64 155 8
Pre-mRNA-processing factor 19 PRPF19 55 0.19 81 7
hypothetical protein LOC55006 FLJ20628 53 0.06 64 2
19 TFIIH basal transcription factor complex p44 subunit GTF2H2 44 0.33 77 12
Isoform 2 of Basic leucine zipper and W2 domain-containing protein 1 BZW1 41 0.08 44 4
20 Cell division protein kinase 7 (TFIIH subunit) CDK7 39 0.3 142 9
Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 36 0.42 190 9
DNA-binding protein RFX5 RFX5 65 0.05 54 3
21 Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 36 2.13 688 77
Regulatory factor X-associated protein RFXAP 28 0.4 79 10
Hypothetical protein DKFZp313O1018 (Fragment) HECTD2 17 0.19 51 7
22 Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 36 0.55 158 10
CDK-activating kinase assembly factor MAT1 (TFIIH subunit) MNAT1 36 0.86 128 17
Cyclin-H (TFIIH subunit) CCNH 38 0.8 128 17
TFIIH basal transcription factor complex p34 subunit GTF2H3 34 0.58 122 12
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 Figure 2.9. Comparison of 15 and 600 seconds of transcription with partially 
purified activity on a linear AdMLP template. All lanes contained TFIIE, 
TFIIH, and dATP.
Linear Template
Time (sec): 15 15 600 600 15 15 600
- +Activity:
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supercoiled template. 
The rate-enhancing activity requires TFIIE. 
 I added recombinant TFIIE, native purified TFIIH, and dATP to the activity assay to 
determine if either, or both, were sufficient for the activity or necessary to observe rate-
enhancement by the purified activity. Analysis determined TFIIE was necessary to produce the 
rate-enhancing activity (Figure 2.10A). The activity-containing fraction used in Figure 2.10A 
was from the final DEAE-5PW column. dATP was not required. Furthermore, TFIIE, TFIIH, and 
dATP without the activity-containing fraction were not sufficient under standard in vitro 
transcription concentrations to produce the accelerated rate. Further tests showed that the factor 
requires both subunits of TFIIE for activity (Figure 2.10B). TFIIH alone does not accelerate the 
rate of promoter escape when used at concentrations sufficient to produce transcript from a linear 
template (Figure 2.10C). From this I concluded that the activity required TFIIE, but not TFIIH or 
dATP.
Immunodepletion studies 
 Using the information from the MASCOT identifications, I performed immunodepletion 
experiments on a few of the top scoring protein matches with documented roles in transcription, 
including topoisomerase II A (TOP2A) and B (TOP2B), Kif2A, and TFIIH. Antibodies 
immobilized on protein A/G beads were used to pull down the respective proteins after which the 
flow-through and beads were assayed for activity using the transcription assay, silver stained, 
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Figure 2.10. A) Partially  purified activity requires TFIIE, but not TFIIH or dATP to 
accelerate the rate of promoter escape. 16 nucleotide product is shown. B) The partially 
purified activity  requires both subunits of TFIIE. Transcription proceeded for 15 seconds. 
C) Transcription at 15 seconds and 600 seconds comparing fractionated activity and 
purified TFIIH reveals that TFIIH does not accelerate the rate of promoter escape when 
used at transcription-dependent concentrations. TFIIE was present in all of these reactions.
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and western blotted for the protein of interest. Activity remained in the flow through for TOP-A, 
TOP-B, and Kif2A immunodepletions (data not shown). The immunoprecipitated TFIIH was 
eluted with a TFIIH epitope peptide and the activity was found to elute with TFIIH (Figure 2.11).
TFIIH can provide rate enhancement in a concentration dependent manner 
 Because the activity immunodepleted with TFIIH and required TFIIE, I decided to further 
investigate the possibility of TFIIH involvement. Figure 2.12A shows 15 seconds of transcription 
with a titration of two different TFIIH preparations (JAG and Taatjes) alongside the partially 
purified activity. The JAG and Taatjes TFIIH stocks were prepared from HeLa nuclear extracts 
following two different purification schemes (91, 158). At the higher concentrations, all three 
show similar levels of transcript, however, at the lower titration points, the JAG TFIIH does not 
show product. The volume of JAG TFIIH added at all these points is sufficient to produce 
transcript from linear templates given 10-20 minutes of transcription. Figure 2.12B compares 
transcription in reactions containing a variety of rate-enhancing fractions and TFIIH at 15 and 
600 second timepoints. None of the preparations required dATP to exhibit activity. In this 
experiment the JAG TFIIH exhibits rate-enhancing activity like the others, however at a volume 
greater than 10 fold higher than we typically add to our assays. In a transcription assay on a 
linear template, transcript levels plateaued with 0.04 µL of the JAG TFIIH (data not shown). 
Therefore, approximately 10 times more TFIIH is required to see rate-enhancement with the JAG 
TFIIH compared to the amount needed to observe maximal levels of transcription from a linear 
template. I conclude that TFIIH is the rate-enhancing factor. Our assays contained a low amount 
of TFIIH during the purification; the chromatography fractions containing the activity 
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Figure 2.11. Transcription assay shows that  the activity immunodepletes 
with α-TFIIH and can be eluted with a TFIIH peptide. All lanes contained 
TFIIE.
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Figure 2.12. A) Transcription assay titrating (0.05, 0.1, 0.5, and 1.0 uL) different TFIIH 
preparations shows the activity is consistent with a high concentration of TFIIH. 
Transcription was terminated after 15 seconds. JAG TFIIH and Taatjes TFIIH are TFIIH 
preps previously purified by  the Goodrich and Taatjes labs, respectively. D.3P.5SQ6H is 
activity purified through the Heparin column. B) Various TFIIH preparations give similar 
accelerated transcription rates on an AdMLP template. JAG TFIIH sample shows rate-
enhancing activity when added at greater than 10 times higher concentration (0.75 uL) than 
required for TFIIH-dependent transcription on a linear template. Samples were assayed for 
15 and 600 seconds of transcription. S- and Q-pools are partially  purified nuclear extracts, 
D.3P.5S and D.3P.5SQ respectively. JAG H and Taatjes H are JAG TFIIH and Taatjes 
TFIIH, respectively.
JAG TFIIH Taatjes TFIIH D.3P.5SQ6HBuffer
15 s 600 s
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substantially increased the concentrations of TFIIH in the transcription reactions and hence 
enhanced the rate of promoter escape.
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DISCUSSION
 In this chapter I described purification of a factor that accelerates the rate of promoter 
escape on negatively supercoiled and linear AdMLP templates in vitro. A two-timepoint 
transcription activity assay was developed in order to monitor the fractionation of the factor 
throughout purification. A seven column chromatography scheme was developed and described. 
The purified fraction was subjected to mass spectroscopy analysis and was found to contain 9 
subunits of TFIIH. The activity immunodepleted with a TFIIH antibody. Moreover, I found that 
titration of two independent TFIIH preparations produced similar rate-accelerating activity, 
however required greater than 10 times more TFIIH than necessary for maximal transcription on 
a linear template. 
 The activity consistently eluted between 0.2 M and 0.3 M KCl during all the ion 
exchange columns used, consistent with some previous purifications of TFIIH (158), but not 
others (58). Furthermore, the sepharose 6 gel exclusion column indicated that the activity eluted 
as a complex approximately 550 to 600 kDa in size. Holo-TFIIH consists of 10 subunits and is 
greater than 500 kD in size (159). Upon characterizing the activity, I found that TFIIE was 
required, but not sufficient to produce the accelerated rate. This is consistent with the activity 
being TFIIH because TFIIE is required to recruit TFIIH into preinitiation complexes (160).
 Two different TFIIH preparations showed rate-enhancing activity upon titration into the 
transcription assay. Since all of the tested TFIIH preparations were purified from human cells, it 
would be interesting to compare the purity of the two preparations with my fraction. This would 
provide insight into whether any other factors may contribute to the activity. Furthermore, each 
TFIIH lot was prepared differently and therefore contained different concentrations of active 
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TFIIH. It appears in these studies that a higher concentration of TFIIH leads to an acceleration in 
the rate of transcription. Western blots for TFIIH confirmed that differences in TFIIH levels 
correlate with differences in rate-enhancing activity for JAG TFIIH, Taatjes TFIIH, and my 
purified activity (data not shown). It is also possible that the TFIIH in each preparation is a 
heterogenous mixture of TFIIH complexes, for example with multiple phosphorylation states, 
and the complex responsible for the activity is more or less abundant in the different 
purifications (161).
 TFIIH is required for transcription beyond 2-3 nucleotides on a linear template (53, 84, 
88, 162). Our studies indicate a different requirement for TFIIH in enhancing the rate of 
promoter escape. Using our in vitro system, I needed greater than 10 times more TFIIH to 
maximize the rate of promoter escape compared to the amount needed to proceed past initiation 
on a linear template. Perhaps the TFIIH releases after initiation and a new TFIIH binds to 
facilitate promoter escape (Figure 2.13). This model explains the higher concentration 
dependence of the rate-enhancing activity of TFIIH. One could test this through release and 
rebinding assays on immobilized templates, or with the addition of competitor DNA to capture 
the released TFIIH.
 It is interesting that TFIIH produces the rate enhancing activity in our in vitro system 
since the negatively supercoiled DNA negates the need for TFIIH helicase activity (82, 85-87). 
TFIIH may create a more stable ternary complex via interactions with Pol II and other 
transcription factors that facilitates structural transformations during the rate-limiting step of 
promoter escape (163). During promoter escape, the upstream region of the transcription bubble 
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Figure 2.13. Transcription complexes show different requirements 
for TFIIH during the early steps of transcription.
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begins to close, which may drive the transcription machinery forward, promoting promoter 
escape (100). TFIIH may participate in this closure which could enhance the rate of promoter 
escape. Interestingly, a follow-up study indicated that TFIIH cannot enhance the rate of 
transcription on a pre-melted mismatched bubble template that cannot close (data not shown). 
This suggests a link between bubble collapse and TFIIH-mediated rate enhancement. 
 TFIIH is known to be a target for transcriptional regulation by activators. The TFIIH 
helicase activity is a target for transcription stimulation by the FUSE binding protein (FPB) 
transcription factor, which acts at the c-myc promoter (147, 164). TFIIH has also been implicated 
in TBP-mediated activation by PC4 and BRCA1 in a minimal transcription system (76, 77). p53 
binds the p62 and helicase subunits of TFIIH, and these interactions may be important for 
transcriptional activation (55, 56). In addition, activator influence on TFIIH may stabilize PICs 
to facilitate transcription (101). It is understandable that TFIIH is a prime target for activation, as 
it is one of the few general transcription factors with enzymatic activity (102).
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MATERIALS AND EXPERIMENTAL METHODS
DNA constructs 
 The negatively supercoiled plasmid used as the DNA template in these studies contained 
the AdMLP promoter from -53 to +10 fused to a 380 basepair G-less cassette (53). The linear 
template used the above plasmid cut with Hind III and EcoRI .
Preparation of Pol II and transcription factors
 Recombinant human TBP, TFIIB, TFIIE, and TFIIF were expressed in E. coli and 
purified as previously described (91). Native human RNA polymerase II and JAG human TFIIH 
were purified from HeLa cells as previously described (91, 165). Taatjes TFIIH, courtesy of D. 
Taatjes, was purified from HeLa cells using the flow through from a Q column followed by 
peptide elution off an anti-ERCC3 monoclonal antibody column as previously described (158).
Transcription reactions
 Transcription reactions were performed in 20 µL of Buffer A: 10% glycerol, 10 mM Tris 
(pH 7.9), 50 mM KCl, 10 mM HEPES (pH 7.9), 4 mM MgCl2, 1 mM DTT, 20 µg/ml BSA, 160 
U RNaseOUTTM (Invitrogen), and 0.02% NP-40. Transcription factors were added at the 
following final concentrations: 3.5 nM TBP, 10 nM TFIIB, 2 nM TFIIF, 9 nM TFIIE-34, 5 nM 
TFIIE-56, 0.7 µL TFIIH, and 1-3 nM Pol II. Proteins (in 10 µL) were incubated at 30oC for 3 
minutes and then 2 nM template DNA (in 10 µL) was added and preinitiation complexes were 
allowed to form for 10 minutes at 30oC. Transcription was initiated by adding a limited 
nucleotide mix, giving final concentrations of 20 µM CTP, 1 µM [α-32P]CTP (5 µCi/reaction), 
58
650 µM UTP, 500 µM ApC dinucleotide (Sigma-Aldrich), 100 µM dATP (Invitrogen), and 
350 µM 3’O-methyl-ATP (3‘O-Methyl-ATP) chain terminator (TriLink BioTechnologies).
 When indicated, nuclear extract or chromatography fractions were added 5 minutes prior 
to NTP addition. At defined time points, transcription was quenched with a stop solution 
containing 3.1 M ammonium acetate, 20 mM EDTA, 10 µg carrier yeast RNA, and 15 µg 
proteinase K. Transcripts were ethanol precipitated using 100% ethanol on dry ice for 25 minutes 
then centrifuged 13,000xg for 50 minutes followed by a 70% ethanol wash. The 15 nucleotide 
product was denatured and resolved with 14% PAGE after which the gel was dried under heat 
and vacuum.
Determination of rate constants
 Gels were scanned using a Molecular Dynamics TyphoonTM Phosphorimager and 
quantitated using ImageQuantTM software. Phosphorimage units (PI) were plotted versus time, 
and the data was fit with the equation PI=PImax(1-e-kt). PrismTM software was used to solve for k 
and PImax. Experiments were normalized using the PImax calculated from the data sets.
Nuclear extraction and chromatography buffers
 HeLa nuclear extracts were prepared and column chromatography performed using the 
following buffers: Buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10mM KCl), Buffer C 
(20 mM HEPES (pH 7.9), 25% glycerol, 417 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA), Buffer 
D (40 mM HEPES, (pH 7.9), 0.05-1 M KCl, 20% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 
1 mM DTT, 0.2 mM PMSF), PBSM (1X PBS, 1.2 mM MgCl2). All buffers were filtered using a 
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0.2 micron filter and used at 4oC. For CHT hydroxyapitate column chromatography (BioRad) the 
following buffers were used: 10 mM, 250 mM, or 500 mM Na-Phosphate buffer (pH 7.6) with 
20% glycerol, and 0.2 mM EDTA. Na-Phosphate buffer contained a 1:1 ratio of Na2HPO4 
monobasic and dibasic. Phenyl sepharose column buffer contained 0.05 M Na-Phosphate buffer 
(pH 7.6) and 1.5 M KCl.
Cell culture and isolation of nuclei
 HeLa cells, courtesy of D. Taatjes, were grown to a density of 0.7 million cells per mL in 
DMEM media and split 1:1 every day, until 100 L of cells were obtained. Cells were harvested in 
8-12 L batches and nuclei were isolated immediately. The cells were resuspended in 5 pellet 
column volumes (PCV) of buffer and incubated on ice for 20 minutes and then centrifuged for 10 
minutes at 3000xg. The pellet was next resuspended with 2 PCV of buffer, dounce homogenized 
7 times using a 20 mL dounce, and centrifuged for 15 minutes at 15,000xg. The isolated nuclei 
were stored as pellets at -80oC. Protease inhibitors and reducing agent were added in all buffers 
throughout the cell harvest and processing (1X Roche complete protease inhibitor cocktail, 1mM 
Na2S2O4, 1 mM DTT, 0.2 mM PMSF). After isolating the nuclei from 100 L of cell culture, the 
nuclei were dounce homogenized to isolate nuclear extract as previously described and dialyzed 
into buffer D.1 (166).
Chromatography
 All chromatography was performed at 4oC in the presence of protease inhibitors and 
reducing agents. All columns were equilibrated with 5 column volumes of buffer prior to sample 
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loading and during each KCl elution step, where applicable. Phosphocellulose P11 (Whatman) 
and DEAE DE52 cellulose (Whatman) columns were prepared and pre-treated according to 
manufacturers specifications and chromatography was executed using gravity flow or peristaltic 
pump at no greater than 2 mL/min. 
 All other chromatography columns were run on either a BioRad HPLC (Source 15S 
column) or PharmaciaBiotech SMART micro-purification system (Source 15Q, Superose 6, 
Heparin, DEAE-5PW columns) and monitored for absorbance at 260 nm and 280 nm. The 
superose 6 PC 3.2/30 24 mL gel filtration column (GE Healthcare) was equilibrated and run 
using Buffer D.1 as the mobile phase at a constant flow for both the sample and standard run on 
the SMART system. A mix of 29,000-700,000 molecular weight standards were used prior to 
sample purification to calibrate MW elution time. The input to the column was filtered and spin 
concentrated to ~500 µL using 5K NMWL membrane micro-concentrator (Millipore) prior to 
loading.
LC-MS/MS
 Samples were resolved by 8.5% SDS-PAGE, visualized with Sypro Ruby stain. Bands 
were in-gel reduced with DTT, alkylated with iodoacetamide, and then trypsin digested for 
identification by the University of Colorado at Boulder Mass Spectroscopy Facility. The samples 
were run on a LC-MS fitted with an electrospray ionizer and an ion-trap detector and peptides 
were analyzed using the MASCOT search engine for the human IPI database.
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Immunodepletions
 Immunodepletion of TFIIH, TOPIIA, TOPIIB, or Kif2A was done at 4oC using HGEN 
wash buffer (15% glycerol, 20 mM HEPES pH 7.9, 0.5mM EDTA, 1 mM DTT, 0.2 mM PMSF). 
A 40 µL portion of Protein A/G agarose beads (Santa Cruz) was incubated with the 
manufacturer's recommended amount of antibody for 1 hour while nutating, followed by an 
additional 1-3 hours of incubation with the partially purified activity. Beads were washed twice 
with HGEN containing 0.1 M KCl followed by three times with HGEN containing 0.3 M KCl, 
and the flow throughs from each wash, along with the beads, were analyzed via western blot and 
silver stain. TFIIH was eluted with a TFIIH peptide as published (158).
Western blot and silver stain detection
 Western blots were performed using standard procedures using TBS wash buffer 
(137 mM NaCl, 20 mM Tris pH 6.5) first with 0.05% Tween and then without Tween. The 
following antibodies were used according to the manufacturer's specifications: αTOPIIA (Santa 
Cruz), polyclonal αTOPIIB (Santa Cruz), polyclonal αKif2A (Novus Biologicals), and αTFIIH 
p89 antibodies (Santa Cruz, or an in house preparation) were used. Secondary antibodies with a 
horseradish peroxidase conjugate, were used at a 1:10,000 dilution, and then detected using ECL 
Plus western blot detection reagents (GE Healthcare). Silver stained samples were SDS-PAGE 
resolved and silver stained following a standard silver stain process.
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CHAPTER 3
Chromatin oligonucleotide precipitation-sequencing (ChOP-seq): Developing a new 
technique to monitor lncRNA occupancy on chromatin
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CHAPTER 3
SUMMARY
 Recently thousands of long noncoding RNAs (lncRNAs) have been discovered in 
mammalian cells (117-119). Researchers have used genome-wide methods including ChIP-
sequencing and RNA tiling experiments to discover these lncRNAs and the regions from which 
they are transcribed, however, at the time this work was begun none had used a genome-wide 
method to determine whether lncRNAs interact with chromatin, and if so, where they are 
located. Here I describe the development of a ChIP-like method we have termed Chromatin 
Oligonucleotide Precipitation, or ChOP, that uses antisense oligonucleotides to precipitate the 
lncRNA of interest from cross-linked cells thereby pulling down any associated chromatin and 
proteins. The oligonucleotide precipitated material is then sequenced using Illumina technology. 
In this study I targeted the well characterized lncRNA HOTAIR. An initial sequencing 
experiment using one candidate oligonucleotide probe to pull down HOTAIR identified a variety 
of regions in the genome as potential HOTAIR binding regions. These results indicate that the 
ChOP assay selectively pulls down some chromatin regions in an RNA-dependent manner. This 
chapter describes a new method to identify the genome-wide association of ncRNAs on 
chromatin, which provides insight into the mechanism and function of uncharacterized ncRNAs.
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INTRODUCTION
 Long non-coding RNAs (lncRNAs) are greater than 200 nucleotides in length and can be 
up to tens of kilobases long (167). They are typically transcribed by RNA polymerase II, 
5’capped, polyadenylated, often spliced, and are evolutionary conserved in mammals (168, 169). 
However, they are not translated into proteins like mature mRNAs. Some lncRNAs have been 
shown to be cell-type and lineage specific (maternal or paternal) (118, 122, 169). 
 LncRNAs are emerging as key regulators of gene expression (116, 170). Hundreds of 
lncRNAs co-immunoprecipitate with chromatin remodeling complexes, such as PRC2, CoREST, 
and JARID1C/SMCX (118). Several lncRNAs have been implicated in transcriptional regulation 
(Evf-2 (136), Alu (137), HOTAIR (123), HOTTIP (139), HOTAIRM1 (140), SRA (171), ANRIL 
(172)), including gene imprinting (XIST/RepA (128, 173), Air (131, 132), Kcnq1ot1 (122)), 
often of developmentally regulated genes or gene family loci. It has been confirmed that a few of 
these lncRNAs are targeted to chromatin (Alu (137), Kcnq1ot1 (122), Air (132), and Xist (173)) 
in a loci specific manner. In order to determine where lncRNAs might localize on chromatin in a 
global manner, we needed a genome-wide method. I set out to create an assay to identify 
genomic regions associated with a lncRNA in order to determine the potential scope of lncRNAs 
in regulating gene expression. I used HOTAIR lncRNA to develop this assay. 
 HOTAIR is a 2158-nucleotide spliced and polyadenylated lncRNA transcribed from the 
HOXC locus. HOTAIR was first identified in microarray experiments designed to screen the 
transcriptional activity across human HOX loci (123). Further study showed that siRNA knock-
down of HOTAIR upregulated gene expression in the HOXD locus and decreased H3K27me3 
chromatin marks (Figure 3.1) (123). Later studies proposed a model in which HOTAIR serves as 
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Figure 3.1. HOTAIR knockdown in primary human fibroblasts A) upregulates transcription 
in HOX D genes and B) decreases H3K27me3 in ChIP-chip experiments. * indicates 
significant increase in transcription over siGFP transfection. (Figure from Rinn et al. 2007 
(123)).
A.
B.
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a tether or a scaffold on which to recruit different chromatin modifying complexes to genomic 
loci to suppress gene expression (141). The first 300 nucleotides at the 5’-end of HOTAIR were 
found to bind PRC2 and the 700 nucleotides at the 3’-end were found to bind the LSD1/
CoREST/REST complex, which contains a H3K4me2 demethylase (Figure 3.2) (141). This 
model strongly suggests HOTAIR will function on the genome, however, its presence on 
chromatin had not been investigated. HOTAIR lncRNA has also been implicated in epigenetic 
and transcriptional disregulation in breast and colorectal cancer during metastasis (144, 175). It 
is therefore important to understand the mechanisms by which HOTAIR regulates transcription 
and epigenetics to more fully understand cancer metastasis and potentially unearth new 
therapeutic targets. 
 To better understand the breadth of transcriptional regulation by HOTAIR, I set out to 
develop and conduct a chromatin oligonucleotide precipitation assay targeting HOTAIR lncRNA 
to purify and identify the genomic regions that HOTAIR is associated with. Oligonucleotide 
probes were designed against HOTAIR and used to pull down the lncRNA and associated 
chromatin from formaldehyde cross-linked cells. The chromatin was tested for recovery of 
HOTAIR-regulated HOXD genes. Eluted chromatin was then deep-sequenced using Illumina 
technology and candidate genes were evaluated for HOTAIR occupancy.
67
Figure 3.2. HOTAIR acts as a scaffold in HeLa and primary foreskin fibroblasts for H3K27 
methylation (PRC2) and H3K4 demethylation (LSD1) factors to silence genes (141). 
HOTAIR interacts with the LSD1-CoREST complex at its 3’-end and with PRC2 at the 5’-
end. (Figure modified from Croce 2010 (174)).
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RESULTS
Overview of chromatin oligonucleotide precipitation method
 I developed a ChIP-like assay (Figure 3.3) that we termed chromatin oligonucleotide 
precipitation, or ChOP, to directly pulldown the lncRNA HOTAIR and any associated chromatin, 
with the goal of identifying genomic regions associated with, and presumably regulated by, 
HOTAIR. In brief, I formaldehyde cross-linked Jurkat, HeLa, or primary foreskin fibroblast 
cells, isolated the insoluble chromatin, solubilized it using sonication and fragmentation with 
DNase 1, and then used the chromatin for ChOP experiments. The ChOP input chromatin was 
first pre-cleared with unblocked beads, incubated with biotin-conjugated oligonucleotide probes, 
and then precipitated with blocked NeutrAvidin agarose beads. The bead-bound chromatin was 
then stringently washed and the lncRNAs, and associated chromatin and proteins, were eluted 
and cross-links were reversed. The recovered DNA was then purified and PCR analyzed for a 
subset of HOXD genes previously shown to be regulated by HOTAIR (123). For Illumina 
sequencing, a library of the eluted DNA was prepared using a commercially available ChIP-seq 
kit.
Optimization of chromatin oligonucleotide precipitation assay
 The original ChOP assay was previously published by our lab, and had been used with 
mouse cells for the 182 nt B2 RNA and with human cells for the 280 nt Alu RNA (137). Besides 
the obvious difference in length between B2 or Alu RNA and HOTAIR, all ncRNAs invariably 
differ in cellular localization, intracellular interactions, structure, stability, sensitivity to buffer 
conditions, and cell-type specificity. I initially set out to optimize the ChOP assay for the 
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Figure 3.3. Schematic of the ChOP-seq assay. Chromatin is cross-linked, fragmented, and 
hybridized to oligonucleotide probes. Chromatin-bound oligo-probes are then precipitated 
with blocked beads. The bound genomic DNA is then purified and sequenced using an 
Illumina Sequencer. (Figure adapted from Valouev et al. 2008 (176)).
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lncRNA HOTAIR. I first needed to find a cell type easily cultured in large quantities that 
contained detectable amounts of HOTAIR. Using RT-PCR, I found that both HeLa and Jurkat 
suspension cells express HOTAIR as shown in Figure 3.4. Both HeLa and Jurkat cells were used 
in the initial optimization experiments.
 To monitor the stability of HOTAIR during the isolation of chromatin, I performed RT-
PCR on cross-linked and non-cross-linked Jurkat cells at various steps in the isolation procedure. 
Figure 3.5 shows HOTAIR levels during cellular fractionation into cytoplasm (cyto), nuclei 
(NP), and then fractionating the nuclei into soluble (NE) and insoluble parts (NE*). Ultimately, 
the input chromatin would be taken from the NE* fraction. I found that cross-linking, and the 
subsequent reversal of cross-links during which the samples are subjected to 65oC for 4-5 hours, 
decreased or eliminated detection of HOTAIR by RT-PCR. This prevented us from monitoring 
HOTAIR during the ChOP assay, which requires cross-linking.
Technical modifications of original ChOP
 Our initial course of action was to optimize the ChOP assay for pulling down the lncRNA 
HOTAIR. To limit RNA degradation, I performed all ChOP processing steps and incubations at 
4oC and subjected samples to the shortest, most efficient incubation periods sufficient to see 
results. The input chromatin and ChOP-purified DNA were stored at -80oC when not being used. 
I determined that two hour incubations, including the oligonucleotide precipitation step, showed 
comparable amounts of precipitated chromatin detected by PCR to that of traditional overnight 
precipitations. 
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Figure 3.4. RT-PCR of RNA from A) HeLa and B) Jurkat cells shows HOTAIR is 
present in both. In the case of Jurkat cells, two amounts of RT sample was tested.
Figure 3.4. RT-PCR of RNA from A) HeLa and B) Jurkat cells shows HOTAIR is 
present in both. In the case of Jurkat cells, two amounts of RT sample was tested.
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Figure 3.5. Detection of HOTAIR RNA by RT-PCR decreases after reversing cross-links for 
5 hours at 65oC, making it difficult to assess HOTAIR levels after ChOP as cross-linking is 
necessary  to precipitate and purify the genomic DNA. Cyto= cytoplasm, NP= Nuclear Pellet, 
NE= nuclear extract, NE*= pellet from nuclear extract.
Figure 3.5. Detection of HOTAIR RNA by RT-PCR decreases after reversing  cross-
links for 5 hours at 65oC, making it difficult to assess HOTAIR levels after ChOP as 
cross-linking is necessary to precipitate and purify the genomic DNA. Cyto= 
cytoplasm, NP= Nuclear Pellet, NE= nuclear extract, NE*= pellet from nuclear 
extract.
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 LncRNAs are anticipated to have secondary and higher order structures. To relax RNA 
structure and make the RNA sequence accessible to the oligonucleotide probes, the probes and 
cross-linked chromatin were incubated at 65oC for 10 minutes and then slowly cooled to 4oC. 
The incubation was also tried at 4oC and at 90oC for 3 minutes, but the 65oC with a slow cool 
resulted in less background in the PCR analysis.
 ChOP wash conditions were extended to 5 minutes with nutation at 4oC with 1mL of 
buffer and 15 µL bead volume, whereas the original ChOP assay utilized 300 µL washes without 
nutation. This volume and incubation time reduced background. ChOP washes included standard 
low salt, high salt, LiCl, and two TE low washes which served to decrease salt concentration for 
negligible ionic interference during the elution step (137). 
 I tested various elution conditions, including the traditional NaHCO3 (pH 8.0) buffered 
elution, an RNase A/T1 and RNase H-assisted elution. The best results came from a published 
ChIP-seq method that eluted during the reverse cross-linking step with 1% SDS (177). This 
elution streamlined the ChOP procedure and showed less background during PCR analysis.
Fragmentation of chromatin for ChOP assays
 I was initially concerned that the extensive sonication of chromatin that is necessary to 
produce the 200-500 basepair fragments required for ChIP assays would also fragment the 
HOTAIR RNA. RT-PCR of sonicated chromatin, shown in Figure 3.6A, appeared to support this 
assumption, as HOTAIR could not be detected after sonication. So I decided to use DNase I as a 
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Figure 3.6. A) RT-PCR of chromatin from HeLa cells with and without sonication reveals no 
detection of HOTAIR RNA after cup sonication. B) Optimization of Jurkat chromatin 
fragmentation using DNase 1.
Figure 3.7. A) RT-PCR of chromatin from HeLa cells with and without sonication 
reveals no detection of HOTAIR RNA after cup sonication. B) Optimization of 
Jurkat chromatin fragmentation using DNase 1. 0.1% formaldehyde cross-linked 
cells were fragmented for 18 minutes with DNase 1 for ChOP assays. 
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more gentle approach to fragmenting the chromatin. I had initial difficulty obtaining 
appropriately sized fragments of Jurkat chromatin, and found that limited cup sonication (1 to 2 
times of 1 minute sustained sonication) followed by limited DNase 1 treatment produced 
satisfactory fragmentation of DNA between 200 and 600 basepairs. Figure 3.6B shows DNase 1 
treatment for 10 to 25 minutes after limited sonication. Our concern about fragmentation of 
HOTAIR upon sonication was later validated by Chu et al. (178).
Oligonucleotide probe design
 I created two pools of DNA oligonucleotide probes that were antisense to HOTAIR with 
the goal of pulling down the RNA in two separate reactions for comparison and validation of 
precipitated chromatin. This comparative analysis was aimed at reducing false positive results 
because identifying overlapping regions of occupancy from the two pulldowns would indicate 
bonafide HOTAIR-associated genes or regions. The probes were designed with high Tm values to 
ensure that the DNA probe:HOTAIR RNA hybrid would survive the ChOP’s stringent washing 
conditions, whereas nonspecific probe interactions would not. The 12 probes, listed in Table 3.1 
and shown in Figure 3.7, were subjected to strict hairpin, and homo- and heterodimer analysis so 
that no hairpins would form during the incubation at 65oC and minimal hetero- and homo-dimer 
base pairing would occur between the oligonucleotide probes. The oligo-probes were also 
analyzed using NCBI Blastn human genomic + transcript pairwise alignment to verify that no 
annealing would occur with endogenous RNAs other than HOTAIR. 
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Table 3.1. Oligonucleotide probes used in ChOP assays. Probes were 5’ conjugated with 
biotin and a triethyleneglycol linker (/5BioTEG/). E=exon followed by exon number (e.g. 
E4= exon 4).
Table 3.1. Oligonucleotide probes used in ChOP assays. Probes were 5’ conjugated 
with biotin and a triethyleneglycol linker (/5BioTEG/). E=exon followed by exon 
number (e.g. E4 = exon 4).
OLIGO SEQUENCE: 5'- /5BioTEG/...
HOTAIR Pool A HOT E1
HOT E3
HOT E5
HOT E6.2
HOT E6.4
HOTAIR Pool B HOT E2
HOT E4
HOT E6.1
HOT E6.3
HOT E6.5
Other E6.662
E6.947
Random
E4 RevComp
CTTTCGGATCAAGCTCCAGAG
CTTCTAAATCCGTTCCATTCCACTG
GTGTAATTGCTGGTTTAGGTTGCAG
ACAAGCCTCATCATAAAGATGGAGA
CACTGCATAATCACTCCTGTATGGA
GGGATATTAGGGACCTGAGGGTCTA
GTCCTCCATTTCAGCCTTTTCTCT
CTCTCTGTACTCCCGTTCCCTAGAT
ATTCTTAAATTGGGCTGGGTCTACA
AAGTGCATACCTACCCAATGTATGG
GAACCCTCTGACATTTGCCT
GACCTTTGCTTCTATGTTCCTCT
GAGTCGTGATACGGTTAGTGTGAGTG
AGAGAAAAGGCTGAAATGGAGGAC
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____________________________________________________________________________________________________TTCACCACATGTAAAACTTTATTTATGCA
TAAAACCACCACACACACACAACCTACACAAGGAATGTGCAGTCCTGAGTCTATTTAGCTACATGTGAGTATATACTCCATAAGGCATATAAAACCAGTGCACAGAAAAT
GCATCCAGATATTAATATATCTACATTTTAAAACTGCATGGAAAATACATTATTATATATACACAAAGTGCATACCTACCCAATGTATGGAAAATATATTCTGTGAGTTGTGTT
TATATACATACTGTGTGTGTACTAAATACATTGAAATTGCATTCTTCTGGGTTCATGAACTGTTTAAGACACAATTCTCTAGCAATCTTAATAGCAGGAGGAAGTTCAGGCA
TTGGGAATGGTAATCTCCATCTGCTGATTTTTTTTCTGTTCTTCTGTACTTCTATTATTTCTGTCTTTTAAATACCCCTTCTGTGTCTACATGCATCACTTATTTAAGTGTTCT
CCTATGTCTATTTTTCTACTGCAACTTTTGTCCCAAGCTGGGGTCTATATTTAGAGTGCAAAGTCCCGTTTGCAGCAGGGTCCCACTGCATAATCACTCCTGTATGGAA
CAAGCATTATATAATTAGGTTACCCATGTGTCTCAAGATGCATTCTTCTAGACCTAATATAAGCATATTATAGAGTTGCTCTGTGCTGCCAGTTAGAAAAGCGGTGCCACT
GTGTCTTGGAGAGGCGTGTAACAGGCAGGTGGATTCCTGGGTGGGTGCTGAACCTTCAAGAGCTTCCAAAGGCTAGGGCTGGTTTCACTTTTAAAAATTTGTTTTTGA
ATCTTAAGTCTAGGAATCAGCACGAAGCAAAGGCTGGACCTTTGCTTCTATGTTCCTCTCAAATTCCGGAGCAGCTCAAGTCCCCTGCATCCAGCCGGGACAGAGAG
GCTTCCGGCCTACACAACCCCTTCGCTTCCTTGTAATTCTTAAATTGGGCTGGGTCTACACAAGTAGCAGGGAAAGGCTTTCCTATAACCCAAGCTTTTTTCCAACAAA
ACACACTCCCAACCCCTTTGGGGAAGCATTTTCTGACACTGAACGGACTCTGTTTGGGCCTCCTAAAATTGGTCCCATTTGGATCTTTCCTTAGCAACTAAAAATCCAG
AACCCTCTGACATTTGCCTATGGAAAAATTATTTGAGAGACAGTGCACTCACGCCCAACAGATATATTGTTTATGAGTCCATGGGTTCCGTGTAGACGCCGCCATATTTT
ACAGTCCAAAGGAATCAATTAATTAGCGCCTCCCAGTCCCCCCACCGACCGCTGCTCGGCTGAGCGGGCGCGGCTGAGATAGAGGTGCTTGGCCAGCTCTCTGGTC
TTGTTAACAAGCCTCATCATAAAGATGGAGATGATAAGAAGAGCAAGGAAGCCCCGGTGGCCGCGAGGGGCGGGGCTTGGTGGGCCCGGTGTGGGGCAGTGGCT
GACCCGAGCCGGGTGCTGCCCCGGCACCCGCTCAGGTTTTTCCAGCGTTCTCTGGGCGTTCATGTGGCGAGCTAGGACCCGGATTATTCTCTCTGTACTCCCGTTC
CCTAGATTTTCCCTTTTCCTCATGGAACACCAAATCAGATTTTAAAAAATAAAAATACATAAACCTCTGTCTGTGAGTGCCCGTCTTGCCCTCTGCCACGTTTGTTCCGG
GAACTGCCGCCTTGCTCCCTTGCCTGCATTTCTCTGCGTGGTTCGCTTTCACCTTCGTCTGGCGCTCTCTTCCCTCCTCTGGCTCTCTCTCTAGCTTCGTGGTTGCTT
TTTCTACCAGGTCGGTACTGGCTTAGGCCCCAACGAG_______________________________________________________________________________________
___________________CTTGGGTGTAATTGCTGGTTTAGGTTGCAGCACTTCTCTCGCCAATGTGCATA_________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
___________________________________CTTATAAGGAAGGCGCCGGTCCTCCATTTCAGCCTTTTCTCTGCCAGGACGCGGCCGTGGCATTTCTGGTCTTGTAAAC
ATCAGACTCTTTGGGGCCTTAAAAAAATAAAGACGCCCCTCCTTC______________________________________________________________________________
______________________________________________________________________________________________________________CTCTCGCCGCCGTCTGTAA
CTCTGGGCTCCCTCTCTCCACTCCCCACTCCCCTACTGCAGGCTTCTAAATCCGTTCCATTCCACTGCGAAGCGGAGCAGGAC_____________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
________________________________________________________________CTTTCTGATTGAGAGCACCTCCGGGATATTAGGGACCTGAGGGTCTAAGTCCCGG
GTGGGAGCCGCCAGGAGCAGGGGTGTTGGTCTGTGGAACTCCCAGGCCTCAGTGCCTGGTGCTCTCTTACC___________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________
___________________________________________________________________________________________________________________CCCACGGAGCAGTC
CTCACTGTGGAAGCTTTCGGATCAAGCTCCAGAGCACAGGCGAGTCAGAGTTCCCCACTGCCTGCCTAGGCTTCCAGGTTCCGGAAATCAGGGCAGAATGT______
______________________________________________________________________________________________
E1
E2
E3
E4
E5
E6
Figure 3.7. DNA sequence shown is the template strand from which HOTAIR RNA is 
transcribed (reverse-complement of the RNA). Exon sequences are displayed (from top to 
bottom E6, E5, E4, E3, E2, and E1, respectively), and introns are shown as lines for 
simplicity. Oligonucleotide probes are underlined and in bold.
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Evaluation of chromatin oligonucleotide precipitation
 To test the effectiveness of our assay during optimization, I PCR amplified the ChOP-
purified DNA for genes in the HOXD cluster (HOXD8, HOXD10, HOXD12, HOXD13) that 
were previously found to be regulated by HOTAIR (123). As a negative control I also PCR 
amplified regions that were presumed not to be controlled by HOTAIR and, therefore, would not 
purify with a HOTAIR probe (IL-2, GAPDH (not shown), and Actin) (123). Since we did not 
know the mechanism of how HOTAIR regulated HOXD genes, I designed three main sets of 
primer pairs to amplify HOXD genes either 200-500 basepairs upstream of the transcription start 
site (TSS) (_p), within 200 bases downstream of the TSS (_a), or in the last exon of each gene 
(_d). These are the primers used in my subsequent optimization experiments.
Optimization of cross-linking for ChOP assay
 I used formaldehyde to create networks of cross-links between RNAs and proteins 
associated with chromatin. As HOTAIR associates with chromatin modifying factors, we 
predicted the HOTAIR RNA would be interacting with chromatin, either directly or indirectly 
(123). A concern was that by under- or over-cross-linking, I would either miss weak interactions 
or yield a high level of background (179). To optimize the cross-links for ChOP, I decided to 
titrate formaldehyde into in vivo cross-linking reactions for 10 or 20 minutes and test the capture 
of HOXD chromatin by the ChOP assay. I tested 0.1, 0.5, and 1% formaldehyde using a pool of 
HOTAIR oligo-probes and compared recovery of various HOXD loci to the SFPQ lncRNA locus 
as a negative control. Figure 3.8 shows that 0.1% formaldehyde cross-linking of Jurkat cells for 
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Figure 3.8. A ChOP was performed with Jurkat cells testing pool B of HOTAIR oligo-probes for 
HOXD gene recovery after formaldehyde cross-linking. Cells were cross-linked for 10 or 20 
minutes with varying percentages of formaldehyde by  volume followed by isolation of insoluble 
chromatin that was fragmented with DNase 1 for 25 minutes at 37oC. Promoter regions (_p) or 
downstream (_d) regions of the genes were targeted in PCR of the eluted chromatin. R= probe 
with random sequence. All other lanes had a pool of HOTAIR oligo-probes. 
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20 minutes produced the greatest recovery of the various HOXD gene regions. The random 
oligo-probe did not pull down any of the HOXD gene regions. The HOTAIR probes did not pull 
down the SFPQ locus. I decided to continue the lncRNA ChOP optimization using the 20 minute, 
0.1% formaldehyde cross-linking condition.
NeutrAvidin beads
 Our previously published ChOP assay captured the biotinylated oligo-probes using an 
antibody against biotin immobilized on agarose beads (Ag) (137). I compared this technology to 
using NeutrAvidin beads (NAg). NeutrAvidin is a chemically modified form of avidin (a cationic 
glycoprotein (pI 10.0) that tightly binds to biotin) in which the carbohydrate moiety is removed 
or deglycosylated. NeutrAvidin has no Arg-Tyr-Asp sequence and has a neutral isoelectric point 
of pH 6.3, thereby supporting very low non-specific binding (ThermoScientific). NeutrAvidin 
has a higher affinity for biotin than an α-biotin antibody, and therefore a reduced binding time. 
 I compared the NeutrAvidin beads with α-biotin-bound protein A/G beads using our 
ChOP assay (Figure 3.9). The ChOP compared a HOTAIR oligo-probe pool to a pool targeting 
another lncRNA (SFPQ) and to the random probe. Upstream region of HOXD12 shows reduced 
background for the random probe in the NAg bead samples but similar levels of HOXD gene 
pulldown with the lncRNA probes. It is not known whether SFPQ lncRNA regulates HOXD, but 
the data show SFPQ localizing to HOXD12. Another control experiment using beads-only versus 
lncRNA specific probes or a random probe also showed reduced nonspecific binding for the NAg 
compared to the antibody-bound Ag beads (not shown). Based on this increased signal to 
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Figure 3.9. ChOP assay titrating oligo-probes for random, HOTAIR pool B, or SFPQ (pool of 
5) compares α-Biotin and NeutrAvidin beads. Assay  shows NeutrAvidin agarose beads 
exhibit reduced nonspecific binding compared to αbiotin-bound agarose beads. PCR of 
HOXD loci is shown.
Figure 3.9. ChOP assay titrating oligo-probes for random, HOTAIR 
pool B, or SFPQ (pool of 5) compares α-Biotin and NeutrAvidin beads. 
Assay shows NeutrAvidin agarose beads exhibit reduced nonspecific 
binding compared to αbiotin-bound agarose beads. PCR of HOXD loci 
is shown.
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background ratio, I used the NeutrAvidin beads in subsequent ChOPs. 
Analysis of oligonucleotide probes
 I wanted to compare the efficiency with which the two different oligonucleotide pools 
pulled down the HOXD locus in the ChOPs. Splitting the HOTAIR probes into two sets 
containing five probes each, I compared the two pools (A and B) and found that the B pool had 
significantly higher genomic recovery at the HOXD12 promoter, and comparable levels at the 
HOXD10 promoter to pool A (Figure 3.10A). Next I compared the oligo-probes within pool B to 
determine if a subset of the probes was more effective for pulling-down HOTAIR, or if any 
probe combinations appeared to decrease precipitation. Figure 3.10B shows a pool of probes 
containing E4, E6.1, and E6.3 precipitated more HOXD loci, and the addition of probes E2 and 
E6.5 were not inhibitory. Testing each probe individually revealed the probe targeting HOTAIR 
exon 4 (HOT E4 probe) was primarily responsible for the higher amount of HOXD pulldown in 
pool B (Figure 3.10C). Oligo-probe E6.3 also pulled down a significant amount of HOXD-
containing chromatin. The E4 and E6.3 probes, along with the random probe, were used in 
subsequent studies.
Illumina sequencing
 Jurkat cell ChOPs, followed by PCR, repeatedly suggested that the E4 oligo-probe was 
pulling down the HOXD locus in a specific manner. I decided to sequence an E4 oligo ChOP 
sample. The sample was prepared using the Illumina ChIP-sequencing amplification kit. Prior to 
submitting the sample for Illumina sequencing, we PCR analyzed the ChOP sample before (E4) 
and after (Seq) amplification with the kit (Figure 3.10D). The E4 and Seq samples showed 
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Figure 3.10. Investigation of probe specificity  for pulling down chromatin in the ChOP assay. 
Equal amounts of probes were pooled and tested in ChOP assays followed by  PCR for recovery 
of HOXD genes. A) HOTAIR pool B recovered greater quantities of DNA than pool A. B) Pool 
B was further divided into two pools and compared. C) Analysis of individual oligo-probes 
revealed that probe E4 precipitates the greatest amount of HOXD12 and HOXD8 promoter 
regions. D) E4 ChOP tested before (E4) and after (Seq) amplification in Illumina sequencing kit. 
Promoter regions (_p), upstream (_a) or downstream (_d) regions of the genes were targeted for 
PCR.
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specificity at the HOXD8 loci, and no signal at the control regions tested (HOXC10, IL-2, and 
GLUD1). The returned Illumina sequences (1377 Mbases) were mapped with Bowtie (180) and 
the mapped sequences were run through the QuEST peak calling software (176), which found 
peaks indicative of HOTAIR binding sites. I opted to use QuEST because I can specify ChOP-
seq peak-calling parameters that represent different peak distribution morphologies: punctate 
(similar to sequence-specific transcription factors), somewhat broad distribution (Pol II-like), or 
very broad distribution (similar to histone marks).
 I used the web-based data analysis program Galaxy to analyze the peaks (181). Peak calls 
were joined with hg19 UCSC Main RefSeq genes which found that approximately 85% of the 
3732 peaks called by QuEST were within RefSeq annotated genes. 1844 different genes 
contained peaks and approximately 53% of the peaks were within introns, whereas 52% of the 
total peaks were within 1000 basepairs of a TSS. Figure 3.11A shows these peak distributions 
along with those in other genomic regions. Figure 3.11B shows the binned tag density of peaks 
within 1000 bases of annotated gene transcriptional start sites. The peaks of occupancy 
concentrated approximately 200 bases upstream and downstream of the TSS. This signature is 
similar to the occupancy patterns of several histone modifications found in ChIP-seq experiments 
(182, 183).
 I performed MEME (Multiple EM for Motif Elicitation) motif analysis of two sets of 
peaks: 1) those from -1000 to +1000 with respect to annotated TSSs (promoter proximal) and 2) 
those not in the 1st category (promoter distal) (Figure 3.12) (184). I ran multiple MEME 
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Figure 3.11. A) Analysis of sequencing peak distribution relative to human RefSeq genes 
reveals varied occupancy. B) Analysis of HOTAIR distribution surrounding the TSS of 
genes containing peaks between -1000 and +1000. The y-axis shows sequence tag 
density for HOTAIR occupancy.
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analyses, with the maximum 300 sequences at a time, using 200 bp of sequence centered around 
each peak. Identified motifs in the promoter proximal data set included purine-rich motifs 
(motifs 1-3), a motif complimentary to the E4 probe (motif 3), and a sequence with 8 bases 
complimentary to the E4 oligo-probe (motif 5). Promoter distal peaks exhibited a GGAAT repeat 
sequence (motifs 9 and 10) and purine-rich sequences (motifs 6-7). MAST (Motif Alignment and 
Search Tool) revealed that both the promoter proximal and promoter distal peaks exhibited 
multiple repeats of the various motifs throughout the 200 bp sequences analyzed (184). The 
HOTAIR-E4 probe had a high CT-content which may have resulted in the precipitation of 
purine-rich motifs from direct interaction with genomic DNA.
 Evaluation of the sequencing data uncovered a few complicating issues. First, two of the 
motifs found in our MEME analysis matched the E4 oligo, which alludes to either direct oligo-
DNA binding or the possibility of the oligo triplexing to the dsDNA. Second, no peaks were 
called within the HOXD loci. New ChOP assays were performed to validate the peaks identified 
in the sequencing data. These ChOPs showed occupancy at several of the Illumina-identified 
peaks, but also at control regions on various chromosomes not identified in the sequencing data. 
Figure 3.13A-C shows three different ChOP experiments testing six HOTAIR oligo-probes or 
beads only for recovery of Illumina peaks (NUBP1, ELP3, and PRMT2) versus IL-2 and CIITA 
negative control regions. ELP3 and NUBP1 were consistently recovered with all the probes, 
however, the control IL-2 region was also repeatedly precipitated.
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Figure 3.12. MEME analysis comparing promoter-proximal and promoter-distal (>1000 
basepairs from a TSS) sequence motifs. 200 bp regions centered around the Illumina-
identified peaks were analyzed 300 at a time. Many of the motifs were found in repeats 
within the 200 basepair regions. Motif 3 is complementary to a section of the E4 oligo-
probe and Motif 5 contains a partial E4 oligo sequence (GGCTGAAA).
Figure 3.12. MEME analysis comparing promoter-proximal and promoter-distal (>1000 
basepairs from a TSS) sequence motifs. 200bp regions centered around the 300 Illumina-
identified peaks were analyzed at a time and listed above. Many of the motifs were found 
in repeats in the 200 basepair sequences. Motif 5 contains a partial E4 oligo sequence 
(GGCTGAAA). 
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Figure 3.13. ChOP-PCR of gene regions identified from Illumina 
sequencing.
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HOTAIR occupies genes outside of the HOXD locus
 Concurrently to sequencing the Jurkat ChOP enriched DNA, a publication from the 
Chang lab (141) identified a set of genes de-repressed by siRNA knockdown of HOTAIR in 
primary foreskin fibroblasts. From this list I designed primers for promoter regions of the 
following genes: JUD1, SCN2A, BDNF, SIRT2, and GATA1. I then purchased the same foreskin 
fibroblast cell line they used and amplified those genes after ChOP assays. Figure 3.14A shows 
RT-PCR verifying HOTAIR expression in the foreskin fibroblast cells. An initial ChOP in the 
foreskin fibroblasts showed patterns of HOTAIR occupancy at the HOXD genes similar to Jurkat 
cells (Figure 3.14B). This experiment included a control oligo-probe that was antisense to the E4 
oligo. I did not expect precipitation with this antisense probe as no RNA is produced that is 
antisense to HOTAIR in this genomic region (123), however the anti-E4 probe pulled down 
select HOXD regions, perhaps by directly binding genomic DNA. 
 Figure 3.14C shows percent precipitation from a ChOP using foreskin fibroblast 
chromatin pre-treated with RNase A/T1 or untreated. I tested for recovery of chromatin in the 
peak regions of genes identified to be regulated by HOTAIR (141). The RNase samples were 
included to determine that the ChOP enrichment depended on RNA and was not due to the oligo-
probe interacting with genomic DNA. Comparing the RNase-treated to untreated samples, the E4 
oligo-probe appeared to successfully pull down the SCN2A promoter in an RNA-dependent 
manner and the E6.3 oligo-probe appeared to pull down all but the SCN2A promoter. The results 
indicate that together the E4 and E6.3 probes pull down all the regions tested in an RNA-specific 
manner.
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Figure 3.14. A) RT-PCR shows HOTAIR in human foreskin fibroblasts. B) ChOP-PCR for 
promoter regions in foreskin fibroblasts shows HOTAIR occupancy at several loci. Negative 
ChOP contained no probe (beads only) and a=oligo-probe antisense to the E4 oligo. C) Foreskin 
fibroblast ChOP-PCR showing %OP for genes identified by Tsai et al. (141). A ChOP assay 
using probes E4, E6.3, or a random sequence was performed on input chromatin pre-treated 
(rRndm, rE4, rE6.3) with RNase A/T1 or untreated chromatin (Rndm, E4, E6.3). PCR products 
of duplicate ChOPs were ran on an agarose gel and quantitated using ImageJ.
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 Lastly, a paper published by Chu et al. in October of 2011, described a ChIRP assay, or 
Chromatin Isolation by RNA Purification, that was nearly identical to our ChOP assay (178). 
They too targeted HOTAIR and sequenced their precipitated DNA. They identified 832 genomic 
sites occupied by HOTAIR in HOTAIR-overexpressed MDA-MB-231 breast cancer cells 
including NFKBIA, SERINC5, ABCA2, and an intergenic region between HOXD3 and 
HOXD4. I tested these four regions for HOTAIR occupancy using the ChOP assay and foreskin 
fibroblasts. Again, comparing ChOPs using RNase pre-treated chromatin alongside untreated 
chromatin, I tested the E4, E6.3, and random probes and found HOTAIR occupancy at all four 
gene loci (Figure 3.15A). The E4 oligo-probe pulled down HOXD3-4 and SERINC5, whereas 
E6.3 oligo pulled down all the regions. Figure 3.15B shows that both the E4 and E6.3 oligo-
probes pulled down HOXD8, but probe E6.3 also pulled down the ACTB negative control region 
above the random oligo. Oligo-probe E4 did not pull-down ACTB or IL-2 above the random 
oligo. From this result, and others, I concluded that both probe E4 and E6.3 pulled-down verified 
HOTAIR-associated genomic regions, however the background precipitation of negative control 
regions remained problematic.
 Lastly, I also compared the 832 ChIRP-seq identified sites to our 3732 ChOP-seq sites 
and found that only 14 overlapped. Of these 14 overlapping regions, 6 were in centromeres, 5 
were mRNA genes and the other 3 were intergenic regions (data not shown). Because the ChIRP 
method was very similar to our ChOP assay, and the Chang lab already used ChIRP to map 
HOTAIR occupancy to the genome, we decided not to pursue further development of the ChOP-
seq assay for investigation of the lncRNA HOTAIR.
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Figure 3.15. A) Foreskin fibroblast ChOP-PCR of genes identified by ChIRP. A ChOP assay 
using probes E4, E6.3 or the random sequence was performed on input chromatin pre-treated 
with RNase A/T1 alongside untreated chromatin. B) ChOP-PCR of HOXD8, along with the 
ACTB and IL2 negative control regions.
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DISCUSSION
 Here I describe the development of the ChOP assay and the genomic regions identified 
by ChOP-seq that are occupied by HOTAIR lncRNA. I optimized many facets of the technique, 
including cross-linking conditions, chromatin fragmentation, bead-type, and other parameters. 
The Illumina sequencing trial of our ChOP from Jurkat cells using the E4 oligo identified 3732 
regions. However, it proved difficult to definitively confirm that the peaks were sites at which 
HOTAIR was localized as opposed to background. Our plan was originally to utilize a second 
oligonucleotide probe for a new ChOP-seq and to identify overlapping peaks, or to look at 
HOTAIR occupancy by ChOP-seq after HOTAIR siRNA knockdown. After Tsai et al. published 
their studies using foreskin fibroblasts, I purchased and began using this cell line (141). In these 
cells, it appeared the ChOP assay was selectively pulling down chromatin in an RNA-dependent 
manner. I had planned to sequence material precipitated from these cells for comparison with the 
Jurkat data, however the recent publication of the ChIRP-seq paper (178) led us to make the 
decision to not further pursue ChOP-seq on HOTAIR. 
 To test the effectiveness of our lncRNA ChOP assay, we operated under the assumption 
that regions of the HOXD locus would be precipitated, and therefore detectable with PCR. Based 
on previous knockdown studies it was clear that HOTAIR regulated gene expression across the 
HOXD locus, however, any specific binding regions for HOTAIR were unknown (123). One 
question we wanted to answer was how HOTAIR was distributed across the HOXD locus. It was 
unknown whether HOTAIR is required at promoters or throughout genes to function in 
transcriptional silencing, or if it uses a central global control region to more broadly control 
expression (185). A single HOTAIR RNA may be capable of associating with PRC2 and relaying 
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an information cascade across multiple nucleosome to cover large genomic regions. The recent 
ChIRP-seq paper (178) identified an intergenic HOTAIR binding event in the region between 
HOXD3 and HOXD4 that may provide evidence that HOTAIR is indeed acting in this manner as 
they did not precipitate any other HOXD regions.
 The ChOP assay could be further improved through use of other cross-linking reagents, 
including the cleavable amine-reactive NHS-esters EGS (Ethylene glycol-bis[succinimidyl 
succinate], 16.1 angstrom spacer) and DSP (N-hydroxysuccinimide (NHS) ester, 12 angstrom 
spacer), or dual cross-linking using formaldehyde and glutaraldehyde, which would facilitate 
expanded networks of cross-links (DNA to histones to chromatin modifying factors to lncRNA) 
(186). The Chang group found glutaraldehyde gave superior results and low background in their 
ChIRP assay (178). 
 Our method of chromatin fragmentation via DNase 1 treatment provides a nice 
alternative to obtain small fragments. DNase 1 treatment raises the obvious concerns that DNase 
hypersensitive regions of open chromatin, including enhancer and promoter regions, could bias 
the assay (187). However, previous publications have shown DNase 1 elicits no sequence 
specific cleavage bias using naked DNA (188). Moreover, sequencing sonicated chromatin has 
also revealed a bias toward open regions including promoters (189).
 A concern during oligonucleotide probe selection is that the oligonucleotide probes have 
the potential to nonspecifically bind to mRNAs, other ncRNAs, or DNA in open genomic 
regions. In addition, HOTAIR RNA exhibits secondary structure and is bound by PRC2 and the 
LSD1/REST/CoREST complex (141), therefore, regions of the lncRNA may be blocked from 
binding some probes. The use of two different oligo-probes or two different pools of oligo-
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probes in separate ChOP assays would circumvent some of these concerns. Our MEME analysis 
in Figure 3.12 identified motifs (Motif 3 and 5) found in a fraction of the regions with similar 
sequence to our HOTAIR E4 probe, which indicates the probe may have pulled down DNA 
directly by partial annealing with the chromatin. The two probe validation method would have 
excluded these regions during data analysis, as they would have only been pulled down by one 
probe set. Another recently published ChOP-like assay, termed CHART (190), also saw direct 
binding of oligos to endogenous DNA regions in Drosophila chromatin.
 The technical differences between ChOP, ChIRP, and CHART methods are outlined in 
Table 3.2. The ChIRP method (178) uses a series of oligonucleotide probes tiled across the entire 
HOTAIR RNA to circumvent the fragmentation of the RNA observed during sonication. They 
also used two pools of oligo-probes to compare recovered DNA sequences and the overlap was 
less than half the peaks in each individual pool. Our method of using DNase to fragment 
chromatin leaves the RNA intact and therefore it is unnecessary to target the entire RNA with a 
large quantity of costly modified probes. Furthermore, for the ChIRP assay the Chang lab used 
cells in which HOTAIR was over-expressed. It is possible that using HOTAIR over-expression 
may have provided results that do not reflect actual HOTAIR binding and activity. The vast 
majority of their regions did not not coincide with our ChOP-seq data. Differences may lie in the 
cell type used; my sequencing data was from Jurkat cells and theirs was from overexpressed 
breast cancer cells. Lastly, the genomic regions identified in their ChIRP-sequencing study do 
not appear to correlate with genes found to be regulated by HOTAIR in their previous fibroblast 
ChIP-chip and microarray experiments (141). In addition, the ChIRP-seq findings were not 
compared to their previous studies that found genes to be regulated by HOTAIR in cells 
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ChOP
(see Ch3 Methods for specifics*)
ChIRP
(see Chu et al. 2011)
CHART
(see Simon et al. 2011)
lncRNA target HOTAIR HOTAIR rox2
Cells Jurkat, HeLa, orForeskin Fibroblasts
MDA-MB-231 Breast cancer 
cells over-expressing HOTAIR
Drosophilia S2 expressing MSL3
Cross-linking
0.1% formaldehyde, 
18-20 min room temperature 
(RT) in PBS
1% glutaraldehyde, 
10 min RT in PBS
1% formaldehyde, 10 min RT,  
followed by nuclei in 
3% formaldehyde, 
30 min, RT in PBS
Chromatin 
enrichment
2 dounce steps dounce followed by nuclei 
disruption in Bioruptor
dounce followed by nuclei 
disruption in sonicator
Fragmentation
Misonix cup sonicator 2×60s 
followed by limited DNase 1 
treatment to 200-500 bp average 
size fragments
Bioruptor 
to 100-500 bp average size 
fragments
Covaris S2 instrument
2-3K bp average size fragments
Probes
5’-Biotin-TEG 
24- or 25-mer probes
1 probe per ChOP
compare 2 ChOPs
3’-Biotin 20-mer probes with 
18 C spacer (against full-length 
HOTAIR sequence)
2 probe sets with 24 probes 
each per ChIRP
3’-Biotin-TEG 24- or 25-mer 
probes with RNase H elution
3 probes per CHART
Beads NeutrAvidin MyOne Streptavidin C1 magnetic
MyOne Streptavidin C1
Hybridization, 
binding
and capture
hybridization 10 min 65oC, 
slow cool to RT* followed by 
2 hour, 4oC
capture 2 hour, 4oC
(750 mM NaCl, 1% SDS, 50 mM 
Tris 7.0, 1 mM EDTA, 15% 
formamide, add DTT, PMSF, PI, 
and Superase-in)
hybridization 4 hours, 37oC
capture 30 min 37oC
(20 mM Hepes pH 7.5, 817 mM 
NaCl, 1.9 M urea, 0.4% SDS, 
5.7 mM EDTA, 0.3 mM EGTA, 
0.03% sodium deoxycholate, 
5×Denhardt’s solution)
capture overnight at RT
Wash
buffers
low KCl, high KCl, LiCl, TE×2* 5 times with wash buffer 
(2x SSC, 0.5% SDS, add DTT 
and PMSF)
5 times with WB250 buffer
 (250 mM NaCl, 10 mM Hepes 
pH 7.5, 2 mM EDTA, 1 mM 
EGTA, 0.2% SDS, 0.1% N-
lauroylsarcosine)
Elution
65oC reverse cross-linking 
followed by RNase A/T1 and 
Proteinase K
 100 µg/ml RNase A and 0.1 
Units/µl RNase H. 2× 37oC
(100 mM NaCl, 10 mM Tris 7.0, 
1 mM EDTA, 0.5% SDS) 
10 Units RNase H/100 µl buffer 
10 min RT (50 mM Hepes pH 
7.5, 75 mM NaCl, 3 mM MgCl2, 
0.125% N-lauroylsarcosine, 
0.025% sodium deoxycholate, 
20 Units⁄mL SUPERasIN, 5 mM 
DTT)
Table 3.2.  Summary of technical differences between ChOP, ChIRP, and CHART.
containing over expressed HOTAIR (144).
 Overall, using different ChOP-like methods, our results, along with those of the Chang 
group further support broad epigenetic control by HOTAIR lncRNA. It will be interesting to 
determine where on the genome other PRC2-associated lncRNAs localize and how this 
contributes to the global control of gene expression. Another ChOP-like assay, termed CHART, 
was also recently published (190). These methods are slightly different. It is likely that different 
methods may work better for different ncRNAs, which will depend on the function, length and 
other properties of the ncRNA of interest. We are likely to see many more studies of this kind 
determining genomic occupancies of a variety of ncRNAs.
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MATERIALS AND EXPERIMENTAL METHODS
Cell culture
 Suspension HeLa (courtesy of D. Taatjes) and Jurkat cells were grown to near confluency 
in JMEM (Sigma) or RPMI (Invitrogen) media, respectively, supplemented with 5% NCS or 
10% FBS, respectively, and 100 U/mL penicillin (Invitrogen) and 100 µg/mL streptomycin 
(Invitrogen). Foreskin fibroblasts (ATCC CRL-2091) were cultured in EMEM (Gibco) media 
supplemented with 10% FBS and 100 U/mL penicillin (Invitrogen) and 100 µg/mL streptomycin 
(Invitrogen) according to ATCC guidelines, and split and harvested during the exponential 
growth phase. Cells were treated with 0.1% formaldehyde for 20 minutes at room temperature. 
Foreskin fibroblasts were first rinsed with 1X PBS to remove any cells in the suspension and 
then adherent cells were resuspended in PBS for the cross-linking procedure. Glycine was added 
to a final concentration of 0.125 M to stop the cross-linking reaction. The cells were washed 
twice with cold PBSM (1X PBS, 1.2 mM MgCl2, 1X Roche complete protease inhibitor cocktail, 
1mM Na2S2O4, 1 mM DTT, 0.2 mM PMSF) and frozen with liquid nitrogen and stored at -80oC. 
Primer pairs used in RT-PCR and PCR analysis
 All primers are listed 5’ to 3’. RT-PCR was done using the HOTAIR primer pairs forward 
AAGTGAAACCAGCCCTAGC and reverse CCCATGTGTCTCAAGATGC. PCR analysis of 
the ChOP reactions included the following primer sets. (_p) promoter, (_a) upstream, or (_d) 
downstream indicate region of gene targeted for PCR. HOXD8_p forward 
GGTGCGTCAAGGGTAAATGT, reverse CCAGATCCTGGCGTTATCAA; HOXD8_a forward 
GCTGTGGTGCGAAAATGC, reverse TACAAACCCCGGCTCTGG; HOXD9_p forward 
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TCAACCTCACCTCTGTAGGG, reverse GCGGTTCGCACTTAAAGG; HOXD10_p forward 
ACAACGCAGGGACCAACC, reverse GGGTCCAAAGGAAAGATCC; HOXD10_d forward 
CATGGCATTTTGAATACATCC, reverse ATCTCACCAAGGACAACTGC; HOXD11_p 
forward GGTGAACAAGAAGCAACAAGC, reverse ACTAGGTGTGAGGGTGTGAGG; 
HOXD12_p forward AAAATTGGGTAGTTTGTGATGC, reverse 
CCACAGAGAGGGTTTCTCC; HOXD12_d forward GTCAACGAATTCATCAACAGG, 
reverse GCGCTTCTTCTTCATACGC; HOXD13_p forward CCTCTTACCTGTGTGAAATGC, 
reverse TTTTTATCCTGTTGCTGAATCC; HOXD13_d forward 
GGTGGGAACTTACATACAGAACC, reverse TATTTTTCTTCTTGGACCTTGG; BDNF_p 
forward TTTAATGAGACACCCACCGCTGCT, reverse 
AGTCACATCGTGGTTCCGATTCTG; BDNF_d forward AAACTCTCAACCACCTTGGC, 
reverse GGGCGTTTGCGTAAATCTAT; SCN2A_a forward 
TGCAGTCTTCTTGGTGCCAGCTTA, reverse AAAGTGGTCCCTCTGCAGA; SCN2A_d 
forward CGTGTTTCAAGGCTACAGCA, reverse CTCTAGCCTCCCAACCTTCC; SIRT2_p 
forward ACTCTAGGGCTCAAATCGGGAACT, reverse 
AACCTGACTCCAGTCCTGAGACTT; GATA2_p forward 
TAGGTAACTGCGCTCGGACTGA, reverse AGCAGTAACTAACCACCAACTGCC; 
GATA2_d forward CCCTCTGAGCCCTTTGTTTA, reverse TTACAAAGGGAGGGCAAACT; 
NUBP_p forward AAAGGCGACGGAATGGAGGAGGT, reverse 
AGTTAGAGCAGCTCCCGACACTTT; ELP1_p forward 
CTCTATCCAGGAACTCTGTCCCAT, AACGTCTGAACGGAGTGGCATCTT reverse ; IL2_p 
forward CATACAGAAGGCGTTAATTGCATGA, reverse 
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CCCAAAGACTGACTGAATGGATGT; CIITA_p forward 
TTTGGTGTGGGAGTAGGCATGGTA, reverse CAGATGCCTCAAGACAAGCTGAGA; 
HOXD3-4_p forward ATAAGTGCGCAGGCAGAAGT, reverse 
CCGCGATTCAATACACACAA; NFKBIA_p forward ACAAGTTCAGCCAGGTGGTC, 
reverse GCCTAGCTGCACTGAGCAAT; SERINC5_p forward 
TTGACTGTTCTGCCCTGATG, reverse AGGGACGGAAAATGAGTCCT; ABCA2_p forward 
CTCTGCCTGTCAAACATGGA, reverse CAACCCCAAAATCCTGTACG. SFPQ_d forward 
TCGTACTGTTAGGCCCTTGG, reverse ACCCTTGCATGAAGAGCACC; GLUD1_d (see 
Mariner et al. (137))
Design of DNA oligonucleotide probes for oligonucleotide precipitation
 DNA oligonucleotides were designed using Integrated DNA Technologies OligoAnalyzer 
3.1, NCBI Blastn, and Oligo Perfect designer software (Invitrogen). Software recommended 
oligonucleotides were analyzed for the following: optimal melting temperatures at various salt 
concentrations, percent GC content, heterodimers, homodimers, secondary structure formation, 
5’- and 3’-end GC content, GGG and nucleotide runs, and genome-wide basic local alignment 
using NCBI Blastn. Probes were ordered with a 5’-end biotin tag with a TEG linker (5’Biotin-
TEG) from IDT. HOTAIR probes: E1, CTTTCGGATCAAGCTCCAGAG;  E2, 
GGGATATTAGGGACCTGAGGGTCTA; 
E3, CTTCTAAATCCGTTCCATTCCACTG; E4, GTCCTCCATTTCAGCCTTTTCTCT; 
E5, GTGTAATTGCTGGTTTAGGTTGCAG; E6.1, CTCTCTGTACTCCCGTTCCCTAGAT; 
E6.2, ACAAGCCTCATCATAAAGATGGAGA; E6.3, ATTCTTAAATTGGGCTGGGTCTACA; 
101
E6.4, CACTGCATAATCACTCCTGTATGGA; E6.5, AAGTGCATACCTACCCAATGTATGG; 
E6.662, GAACCCTCTGACATTTGCCT;  E6.947, GACCTTTGCTTCTATGTTCCTCT;  
and reverse complement to E4, AGAGAAAAGGCTGAAATGGAGGAC. SFPQ probes: 
GATAAAGATTGGGGGTAAGTTACAG, GGGTATATGAAGTAAGAGTTCCCTG, 
CTCTTTATTGGGGAAAAGTGAGAC, CCCATCAGGGTTCTATGTAATTTAG, 
TACCTCATTCTTTCCCATCTAAGTC, AAATCATTAAGTGAAAGGCAGTAAA, 
TCTAACACCCAATCACTAAACCAC, AAGTTGTGCTTTTGAAGACTTAGGT. Random 
probe: GAGTCGTGATACGGTTAGTGTGAGTG.
Preparation of chromatin
 Cells were resuspended in 5 packed cell volumes (PCV) of Buffer A (10 mM HEPES, pH 7.9, 
1.5 mM MgCl2, 10 mM KCl, 1X Protease Inhibitor Cocktail, 1 mM Na2S2O4, 1 mM DTT, 
0.2 mM PMSF) and incubated for 20 minutes on ice, followed by centrifugation for 10 minutes 
at 4oC at 3000 rpm. Pellets were resuspended in 2.5 PCVs of Buffer A and dounce homogenized 
7 times on ice. Nuclear pellets were recovered by spinning 10 min at 3000 rpm. Pellets were 
resuspended in 2 PCV Buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 417 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1X Protease Inhibitor Cocktail, 1 mM Na2S2O4, 1 mM DTT, 0.2 mM 
PMSF) and dounce homogenized 20 times on ice, then incubated with nutation for 30 minutes at 
4oC. Nuclear extract and the nuclear insoluble chromatin pellet were separated by centrifugation 
at 15,000 rpm for 30 min at 4oC then frozen with liquid nitrogen and stored at -80oC for up to 1.5 
months.
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Fragmentation of chromatin
 Chromatin was fragmented using a Misonix XL2020 sonicator cup horn at power 4.5 two 
times for 1.5 minutes with 1 minute rest in between sonications. Insoluble chromatin pellets were 
resuspended to a concentration of 60 million cells per 1.5 mL with DNase1 buffer (10 mM Tris-
HCl, pH 7.9, 2.5 mM MgCl2, 0.5 mM CaCl2, 10 mM NaCl, 0.05% NP40, 25 U/mL SUPERase-
IN (Invitrogen)) in 2 mL sonication tubes. 10 units of RQ1 RNase-Free DNase1 (Promega) was 
added and allowed to incubate for 20 minutes at 37oC. The fragmentation was quenched by 
adding 10 mM EDTA at 4oC followed by centrifugation for 15 minutes to recover the fragmented 
supernatant, which was then stored at -80oC. Fragmentation was confirmed by running reverse 
cross-linked, purified DNA on a 1% agarose gel at 130 V for 25 minutes. Chromatin was reverse 
cross-linked in 200 mM NaCl for 4 hours at 65oC, RNase A/T1 (Ambion) treated for 30 minutes 
at 37oC, Proteinase K treated for 70 minutes at 55oC, phenol chloroform extracted, and ethanol 
precipitated to obtain reverse cross-linked, purified DNA (177).
Chromatin oligonucleotide precipitation assays
 ChOPs were done using chromatin prepared from 1 x 107 cells for Jurkat and HeLa or 
2.5 x 106 cells for foreskin fibroblasts and resuspended in 1 mL of DB40 buffer (16.7 mM Tris-
HCl, pH 7.9, 167 mM NaCl, 10 mM EDTA, 0.5% NP40, 0.2 mM PMSF, 25 U/mL SUPERase-
IN (Invitrogen)). NeutrAvidin beads were washed 3 times with DB40 buffer and 50 µL 50% bead 
slurry was used to pre-clear chromatin for 2 hours at 4oC. 100 µL of input chromatin (10%) was 
placed at 4oC for later analysis. NAg beads were centrifuged at 2,000 rpm unless specified. 
103
30 µL/sample washed NeutrAvidin beads were blocked for 2 hours at 4oC with 800 µg/mL 
yRNA and 1600 µg/mL BSA. 
 Pre-cleared chromatin was centrifuged at 3,500 rpm for 10 minutes and the chromatin 
supernatant was transferred to new tubes and centrifuged again. 75 pmoles oligonucleotide probe 
were incubated for 10 minutes with chromatin at 65oC, then slowly cooled to 4oC by placing a 
65oC sample heatblock at room temperature for 10 minutes. The samples were then nutated at 
4oC for the remainder of the 2 hour incubation. After washing the blocked beads 3 times with 
DB40, 30 µL of the 50% NAg bead slurry was added to the pre-incubated oligonucleotide probe 
and chromatin tubes and nutated at 4oC for 2 hours for oligonucleotide precipitation. 
 The oligonucleotide precipitation was then subjected to a series of washes to reduce 
background. The samples were washed for 5 minutes while nutating at 4oC using, sequentially, 
1 mL of low salt (20 mM Tris-HCl, pH 7.9, 150 mM NaCl, 10 mM EDTA, 1X Triton, 0.1% 
SDS), high salt (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 10 mM EDTA, 1X Triton, 0.1% SDS), 
LiCl wash buffer (10 mM Tris-HCl, pH 7.9, 250 mM LiCl, 10 mM EDTA, 1% Deoxycholate, 
1% NP40), followed by two quick washes with TE (10 mM Tris-HCl, pH 7.9, 1 mM EDTA) to 
wash away remaining salt in the samples. The washes were centrifuged for 3 minutes at 2,000 
rpm and any remaining supernatant removed with a 10 µL pipette. For the second TE wash the 
samples were transferred to new 0.7 mL eppendorf tubes to reduce background. 
 100 µL input samples were diluted with 300 µL TE and treated the same as ChOP samples 
for the remainder of the protocol. Purification of DNA from these samples followed the method 
outlined by Schmidt et al. (177). Samples were eluted and cross-links reversed for 12-15 hours at 
65oC with elution buffer (50 mM Tris-HCl, pH 7.9, 10 mM EDTA, 1% SDS) with gentle 
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resuspension every 5 minutes for the first 15 minutes. Samples were diluted 2-fold with TE and 
RNase treated with 8 µL of an RNase A/T1 cocktail (Ambion) for 30 minutes at 37oC. Proteins 
in the sample were degraded using 80 µg Proteinase K in 5mM CaCl2 for 65 minutes at 55oC. 
After a 5 minute centrifugation at 8,000 rpm the eluate was transferred to new 1.5 mL eppendorf 
tubes for phenol:chloroform extraction followed by ethanol precipitation. The samples were 
resuspended in 50 µL milliQ water and stored at -80oC for PCR analysis.
Preparation of sample for Illumina sequencing
 After purification of the oligonucleotide-precipitated genomic DNA, the DNA was subjected 
to a series of modifications (blunt end the DNA, add A bases, and ligate sequencing adapters) 
using the Illumina ChIP-Sequencing Kit (Illumina) as per the Illumina instructions, except the 
DNA was subjected to PCR amplification before gel purification and not after. The modified 
DNA was then quantitated using a calf-thymus DNA standard curve, Quant-iT Picogreen reagent 
(Invitrogen), and a Tecan Safire II spectrophotometer. Samples were re-tested via PCR using 
controls to determine retention of sample quality post sequencing kit amplification. Samples 
were analyzed on an Illumina-based GAII system at the Tufts University School of Medicine 
genomics facility, yielding 40 nucleotide reads.
Analysis of sequencing data
 The Illumina sequencing produced 1377 Mbases of sequence reads. Illumina sequences 
were aligned with the hg18 and hg19 human assemblies using Bowtie software yielding ~80% 
aligned reads (180). Peak calls were generated using QuEST v2.4 under 1) transcription factor-
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like, 2) Pol II-like, or 3) histone-like peak parameters and a 4 basepair peak call window (176). 
Peak calls were then analyzed using the web-based platform Galaxy (181). 
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